AB 1843: Communicable diseases: hepatitis C.
- Session Year: 2025-2026
- House: Assembly
- Latest Version Date: 2026-09-27
Current Status:
Passed
(2026-09-27: Chaptered by Secretary of State - Chapter 552, Statutes of 2026.)
Introduced
In Committee
Awaiting First Chamber Vote
Passed First Chamber
In Committee
Awaiting Second Chamber Vote
Passed Second Chamber
Enacted
Existing law, the Knox-Keene Health Care Service Plan Act of 1975, provides for the licensure and regulation of health care service plans by the Department of Managed Health Care and makes a willful violation of the act a crime. Existing law also provides for the regulation of health insurers by the Department of Insurance. Existing law generally prohibits a health care service plan or health insurer from subjecting antiretroviral drugs that are medically necessary for the prevention of HIV/AIDS to prior authorization or step therapy.
This bill would prohibit a health care service plan and health insurer from subjecting direct-acting antiviral drugs that are medically necessary for the treatment of hepatitis C to prior authorization. The bill would specify that these provisions do not require a health care service plan or health insurer to cover all therapeutically equivalent versions without prior authorization, as specified. Because a violation of these provisions by a health care service plan would be a crime, this bill would impose a state-mandated local program.
The California Constitution requires the state to reimburse local agencies and school districts for certain costs mandated by the state. Statutory provisions establish procedures for making that reimbursement.
This bill would provide that no reimbursement is required by this act for a specified reason.
Existing law, the Knox-Keene Health Care Service Plan Act of 1975, provides for the licensure and regulation of health care service plans by the Department of Managed Health Care and makes a willful violation of the act a crime. Existing law also provides for the regulation of health insurers by the Department of Insurance. Existing law generally prohibits a health care service plan or health insurer from subjecting antiretroviral drugs that are medically necessary for the prevention of HIV/AIDS to prior authorization or step therapy.
This bill would prohibit a health care service plan and health insurer from subjecting direct-acting antiviral drugs that are medically necessary for the treatment of hepatitis C to prior authorization. The bill would specify that these provisions do not require a health care service plan or health insurer to cover all therapeutically equivalent versions without prior authorization, as specified. Because a violation of these provisions by a health care service plan would be a crime, this bill would impose a state-mandated local program.
The California Constitution requires the state to reimburse local agencies and school districts for certain costs mandated by the state. Statutory provisions establish procedures for making that reimbursement.
This bill would provide that no reimbursement is required by this act for a specified reason.
Existing law, the Knox-Keene Health Care Service Plan Act of 1975, provides for the licensure and regulation of health care service plans by the Department of Managed Health Care and makes a willful violation of the act a crime. Existing law also provides for the regulation of health insurers by the Department of Insurance. Existing law generally prohibits a health care service plan or health insurer from subjecting antiretroviral drugs that are medically necessary for the prevention of HIV/AIDS to prior authorization or step therapy.
This bill would prohibit a health care service plan and health insurer from subjecting direct-acting antiviral drugs that are medically necessary for the treatment of hepatitis C to prior authorization. The bill would specify that these provisions do not require a health care service plan or health insurer to cover all therapeutically equivalent versions without prior authorization, as specified. Because a violation of these provisions by a health care service plan would be a crime, this bill would impose a state-mandated local program.
The California Constitution requires the state to reimburse local agencies and school districts for certain costs mandated by the state. Statutory provisions establish procedures for making that reimbursement.
This bill would provide that no reimbursement is required by this act for a specified reason.
Existing law, the Knox-Keene Health Care Service Plan Act of 1975, provides for the licensure and regulation of health care service plans by the Department of Managed Health Care and makes a willful violation of the act a crime. Existing law also provides for the regulation of health insurers by the Department of Insurance. Existing law generally prohibits a health care service plan or health insurer from subjecting antiretroviral drugs that are medically necessary for the prevention of HIV/AIDS to prior authorization or step therapy.
This bill would prohibit a health care service plan and health insurer from subjecting direct-acting antiviral drugs that are medically necessary for the treatment of hepatitis C to prior authorization. The bill would specify that these provisions do not require a health care service plan or health insurer to cover all therapeutically equivalent versions without prior authorization, as specified. The bill would require a health care service plan and health insurers clinical criteria for hepatitis C treatment and prior authorization to align with current guidelines and the standard of care consistent with the standards of the American Association for the Study of Liver Diseases and the Infectious Diseases Society of America or generally accepted clinical practice guidelines of another nonprofit health care provider professional association or specialty society pertaining to clinical hepatology or infectious disease. The bill would prohibit a plan or insurer, for the purpose of determining prior authorization for hepatitis C treatment, from requesting specified tests or information. Because a violation of these provisions by a health care service plan would be a crime, this bill would impose a state-mandated local program.
The California Constitution requires the state to reimburse local agencies and school districts for certain costs mandated by the state. Statutory provisions establish procedures for making that reimbursement.
This bill would provide that no reimbursement is required by this act for a specified reason.
Existing law, the Knox-Keene Health Care Service Plan Act of 1975, provides for the licensure and regulation of health care service plans by the Department of Managed Health Care and makes a willful violation of the act a crime. Existing law also provides for the regulation of health insurers by the Department of Insurance. Existing law generally prohibits a health care service plan or health insurer from subjecting antiretroviral drugs that are medically necessary for the prevention of HIV/AIDS to prior authorization or step therapy.
This bill would prohibit a health care service plan and health insurer from subjecting direct-acting antiviral drugs that are medically necessary for the treatment of hepatitis C to prior authorization. The bill would specify that these provisions do not require a health care service plan or health insurer to cover all therapeutically equivalent versions without prior authorization. The bill would prohibit a health care service plan and health insurer from imposing prior authorization requirements, as specified, and authorization, as specified. The bill would require a health care service plan and health insurers clinical criteria for hepatitis C treatment and prior authorization to align with current guidelines and the standard of care consistent with the standards of the American Association for the Study of Liver Diseases and the Infectious Diseases Society of America. Diseases and the Infectious Diseases Society of America or generally accepted clinical practice guidelines of another nonprofit health care provider professional association or specialty society pertaining to clinical hepatology or infectious disease. The bill would prohibit a plan or insurer, for the purpose of determining prior authorization for hepatitis C treatment, from requesting specified tests or information. Because a violation of these provisions by a health care service plan would be a crime, this bill would impose a state-mandated local program.
The California Constitution requires the state to reimburse local agencies and school districts for certain costs mandated by the state. Statutory provisions establish procedures for making that reimbursement.
This bill would provide that no reimbursement is required by this act for a specified reason.
Existing law, the Knox-Keene Health Care Service Plan Act of 1975, provides for the licensure and regulation of health care service plans by the Department of Managed Health Care and makes a willful violation of the act a crime. Existing law also provides for the regulation of health insurers by the Department of Insurance. Existing law generally prohibits a health care service plan or health insurer from subjecting antiretroviral drugs that are medically necessary for the prevention of HIV/AIDS to prior authorization or step therapy.
This bill would prohibit a health care service plan and health insurer from subjecting direct-acting antiviral drugs that are medically necessary for the treatment of hepatitis C to prior authorization. The bill would specify that these provisions do not require a health care service plan or health insurer to cover all therapeutically equivalent versions without prior authorization. The bill would prohibit a health care service plan and health insurer from imposing prior authorization requirements, as specified, and would require a health care service plan and health insurers clinical criteria for hepatitis C treatment to align with current guidelines and the standard of care consistent with the standards of the American Liver Foundation and Association for the Study of Liver Diseases and the Infectious Diseases Society of America. Because a violation of these provisions by a health care service plan would be a crime, this bill would impose a state-mandated local program.
Existing law requires public health records related to human immunodeficiency virus or acquired immunodeficiency syndrome, containing personally identifying information, that were developed or acquired by a state or local public health agency, or an agent of that agency, to be confidential and not disclosed, except as otherwise provided by law for public health purposes or pursuant to a written authorization by the person who is the subject of the record or by their guardian or conservator. Existing law additionally authorizes disclosure when the confidential information is necessary for the coordination of, linkage to, or reengagement in care for a person. Existing law makes disclosure of confidential public health records punishable by various civil penalties or as a misdemeanor, as specified. This bill would make public health records relating to hepatitis B and hepatitis C, containing personally identifying information, that were developed or acquired by a local health agency, or an agent of that agency, to be confidential and not disclosed, except as otherwise provided by law or with the written consent of the person who is the subject of the record or by their legal representative. The bill would authorize a local health officer to disclose any information when necessary to facilitate clinical management, treatment coordination, and prevent the spread of disease or occurrence of additional cases. The bill would apply existing civil and criminal penalties to unauthorized disclosures of confidential public health records covered by these provisions. By expanding the scope of an existing crime, this bill would impose a state-mandated local program.Existing constitutional provisions require that a statute that limits the right of access to the meetings of public bodies or the writings of public officials and agencies be adopted with findings demonstrating the interest protected by the limitation and the need for protecting that interest.This bill would make legislative findings to that effect.The California Constitution requires the state to reimburse local agencies and school districts for certain costs mandated by the state. Statutory provisions establish procedures for making that reimbursement.
This bill would provide that no reimbursement is required by this act for a specified reason.
Existing law, the Knox-Keene Health Care Service Plan Act of 1975, provides for the licensure and regulation of health care service plans by the Department of Managed Health Care and makes a willful violation of the act a crime. Existing law also provides for the regulation of health insurers by the Department of Insurance.
This bill would prohibit a health care service plan and health insurer from subjecting direct-acting antiviral drugs that are medically necessary for the treatment of hepatitis C to prior authorization. The bill would specify that these provisions do not require a health care service plan or health insurer to cover all therapeutically equivalent versions without prior authorization. The bill would prohibit a health care service plan and health insurer from imposing prior authorization requirements, as specified, and would require a health care service plan and health insurers clinical criteria for hepatitis C treatment to align with current guidelines and the standard of care consistent with the standards of the American Liver Foundation and Infectious Diseases Society of America. Because a violation of these provisions by a health care service plan would be a crime, this bill would impose a state-mandated local program.
Existing law requires public health records related to human immunodeficiency virus or acquired immunodeficiency syndrome, containing personally identifying information, that were developed or acquired by a state or local public health agency, or an agent of that agency, to be confidential and not disclosed, except as otherwise provided by law for public health purposes or pursuant to a written authorization by the person who is the subject of the record or by their guardian or conservator. Existing law additionally authorizes disclosure when the confidential information is necessary for the coordination of, linkage to, or reengagement in care for a person. Existing law makes disclosure of confidential public health records punishable by various civil penalties or as a misdemeanor, as specified.
This bill would make public health records relating to hepatitis B and hepatitis C, containing personally identifying information, that were developed or acquired by a local health agency, or an agent of that agency, to be confidential and not disclosed, except as otherwise provided by law or with the written consent of the person who is the subject of the record or by their legal representative. The bill would authorize a local health officer to disclose any information when necessary to facilitate clinical management, treatment coordination, and prevent the spread of disease or occurrence of additional cases. The bill would apply existing civil and criminal penalties to unauthorized disclosures of confidential public health records covered by these provisions. By expanding the scope of an existing crime, this bill would impose a state-mandated local program.
Existing constitutional provisions require that a statute that limits the right of access to the meetings of public bodies or the writings of public officials and agencies be adopted with findings demonstrating the interest protected by the limitation and the need for protecting that interest.
This bill would make legislative findings to that effect.
The California Constitution requires the state to reimburse local agencies and school districts for certain costs mandated by the state. Statutory provisions establish procedures for making that reimbursement.
This bill would provide that no reimbursement is required by this act for a specified reason.
(a)A health care service plan shall not subject direct-acting antiviral drugs that are medically necessary for the treatment of hepatitis C to prior authorization, except as provided in subdivision (b).
(b)If the United States Food and Drug Administration has approved one or more therapeutic equivalents of a pangenotypic drug, device, or product for the treatment of hepatitis C, this section does not require a health care service plan to cover all of the therapeutically equivalent versions without prior authorization, if at least one pangenotypic and therapeutically equivalent version is covered without prior authorization.
(c)This section does not apply to Medi-Cal managed care contracts with the State Department of Health Care Services entered into pursuant to Chapter 7 (commencing with Section 14000) of, or Chapter 8 (commencing with Section 14200) of, Part 3 of Division 9 of the Welfare and Institutions Code.
SEC. 2.Section 10123.1938 is added to the Insurance Code, to read:10123.1938.(a)A health insurer shall not subject direct-acting antiviral drugs that are medically necessary for the treatment of hepatitis C to prior authorization, except as provided in subdivision (b).
(b)If the United States Food and Drug Administration has approved one or more therapeutic equivalents of a pangenotypic drug, device, or product for the treatment of hepatitis C, this section does not require a health insurer to cover all of the therapeutically equivalent versions without prior authorization, if at least one pangenotypic and therapeutically equivalent version is covered without prior authorization.
SEC. 3.No reimbursement is required by this act pursuant to Section 6 of Article XIIIB of the California Constitution because the only costs that may be incurred by a local agency or school district will be incurred because this act creates a new crime or infraction, eliminates a crime or infraction, or changes the penalty for a crime or infraction, within the meaning of Section 17556 of the Government Code, or changes the definition of a crime within the meaning of Section 6 of Article XIIIB of the California Constitution.
(a)A health care service plan shall not subject direct-acting antiviral drugs that are medically necessary for the treatment of hepatitis C to prior authorization, except as provided in subdivision (b).
(b)If the United States Food and Drug Administration has approved one or more therapeutic equivalents of a pangenotypic drug, device, or product for the treatment of hepatitis C, this section does not require a health care service plan to cover all of the therapeutically equivalent versions without prior authorization, if at least one pangenotypic and therapeutically equivalent version is covered without prior authorization.
(c)This section does not apply to Medi-Cal managed care contracts with the State Department of Health Care Services entered into pursuant to Chapter 7 (commencing with Section 14000) of, or Chapter 8 (commencing with Section 14200) of, Part 3 of Division 9 of the Welfare and Institutions Code.
SEC. 2.Section 10123.1938 is added to the Insurance Code, to read:10123.1938.(a)A health insurer shall not subject direct-acting antiviral drugs that are medically necessary for the treatment of hepatitis C to prior authorization, except as provided in subdivision (b).
(b)If the United States Food and Drug Administration has approved one or more therapeutic equivalents of a pangenotypic drug, device, or product for the treatment of hepatitis C, this section does not require a health insurer to cover all of the therapeutically equivalent versions without prior authorization, if at least one pangenotypic and therapeutically equivalent version is covered without prior authorization.
SEC. 3.No reimbursement is required by this act pursuant to Section 6 of Article XIIIB of the California Constitution because the only costs that may be incurred by a local agency or school district will be incurred because this act creates a new crime or infraction, eliminates a crime or infraction, or changes the penalty for a crime or infraction, within the meaning of Section 17556 of the Government Code, or changes the definition of a crime within the meaning of Section 6 of Article XIIIB of the California Constitution.
(a)A health care service plan shall not subject direct-acting antiviral drugs that are medically necessary for the treatment of hepatitis C to prior authorization, except as provided in subdivision (b).
(b)If the United States Food and Drug Administration has approved one or more therapeutic equivalents of a pangenotypic drug, device, or product for the treatment of hepatitis C, this section does not require a health care service plan to cover all of the therapeutically equivalent versions without prior authorization, if at least one pangenotypic and therapeutically equivalent version is covered without prior authorization.
(c)This section does not apply to Medi-Cal managed care contracts with the State Department of Health Care Services entered into pursuant to Chapter 7 (commencing with Section 14000) of, or Chapter 8 (commencing with Section 14200) of, Part 3 of Division 9 of the Welfare and Institutions Code.
SEC. 2.Section 10123.1937 is added to the Insurance Code, to read:10123.1937.SEC. 2.Section 10123.1938 is added to the Insurance Code, to read:10123.1938.(a)A health insurer shall not subject direct-acting antiviral drugs that are medically necessary for the treatment of hepatitis C to prior authorization, except as provided in subdivision (b).
(b)If the United States Food and Drug Administration has approved one or more therapeutic equivalents of a pangenotypic drug, device, or product for the treatment of hepatitis C, this section does not require a health insurer to cover all of the therapeutically equivalent versions without prior authorization, if at least one pangenotypic and therapeutically equivalent version is covered without prior authorization.
SEC. 3.No reimbursement is required by this act pursuant to Section 6 of Article XIIIB of the California Constitution because the only costs that may be incurred by a local agency or school district will be incurred because this act creates a new crime or infraction, eliminates a crime or infraction, or changes the penalty for a crime or infraction, within the meaning of Section 17556 of the Government Code, or changes the definition of a crime within the meaning of Section 6 of Article XIIIB of the California Constitution.
(a)(1)A health care service plan shall not subject direct-acting antiviral drugs that are medically necessary for the treatment of hepatitis C to prior authorization, except as provided in paragraph (2). subdivision (b).
(2)(b)If the United States Food and Drug Administration has approved one or more therapeutic equivalents of a pangenotypic drug, device, or product for the treatment of hepatitis C, this section does not require a health care service plan to cover all of the therapeutically equivalent versions without prior authorization, if at least one pangenotypic and therapeutically equivalent version is covered without prior authorization.
(b)A health care service plans clinical criteria for hepatitis C treatment and prior authorization shall align with the current guidelines and the standard of care consistent with the standards of the American Association for the Study of Liver Diseases and the Infectious Diseases Society of America or generally accepted clinical practice guidelines of another nonprofit health care provider professional association or specialty society pertaining to clinical hepatology or infectious disease. A plan shall not request, for the purpose of determining prior authorization for hepatitis C treatment, any of the following:(1)A liver biopsy.(2)Genotype testing.(3)Proof of sobriety.(4)Fibrosis staging thresholds.(5)Documentation of elastography or other measures of liver stiffness.(6)Ultrasound documentation.(7)A specialist referral or evaluation.(c)This section does not apply to Medi-Cal managed care contracts with the State Department of Health Care Services entered into pursuant to Chapter 7 (commencing with Section 14000) of, or Chapter 8 (commencing with Section 14200) of, Part 3 of Division 9 of the Welfare and Institutions Code.
SEC. 2.Section 10123.1936 is added to the Insurance Code, to read:10123.1936.SEC. 2.Section 10123.1937 is added to the Insurance Code, to read:10123.1937.(a)(1)A health insurer shall not subject direct-acting antiviral drugs that are medically necessary for the treatment of hepatitis C to prior authorization, except as provided in paragraph (2). subdivision (b).
(2)(b)If the United States Food and Drug Administration has approved one or more therapeutic equivalents of a pangenotypic drug, device, or product for the treatment of hepatitis C, this section does not require a health insurer to cover all of the therapeutically equivalent versions without prior authorization, if at least one pangenotypic and therapeutically equivalent version is covered without prior authorization.
(b)A health insurers clinical criteria for hepatitis C treatment and prior authorization shall align with the current guidelines and the standard of care consistent with the standards of the American Association for the Study of Liver Diseases and the Infectious Diseases Society of America or generally accepted clinical practice guidelines of another nonprofit health care provider professional association or specialty society pertaining to clinical hepatology or infectious disease. An insurer shall not request, for the purpose of determining prior authorization for hepatitis C treatment, any of the following:(1)A liver biopsy.(2)Genotype testing.(3)Proof of sobriety.(4)Fibrosis staging thresholds.(5)Documentation of elastography or other measures of liver stiffness.(6)Ultrasound documentation.(7)A specialist referral or evaluation.SEC. 3.No reimbursement is required by this act pursuant to Section 6 of Article XIIIB of the California Constitution because the only costs that may be incurred by a local agency or school district will be incurred because this act creates a new crime or infraction, eliminates a crime or infraction, or changes the penalty for a crime or infraction, within the meaning of Section 17556 of the Government Code, or changes the definition of a crime within the meaning of Section 6 of Article XIIIB of the California Constitution.
(a)(1)A health care service plan shall not subject direct-acting antiviral drugs that are medically necessary for the treatment of hepatitis C, including, but not limited to, sofosbuvir/velpatasvir, sofosbuvir/ledipasvir, glecaprevir/pibrentasvir, or elbasvir/grazoprevir, C to prior authorization, except as provided in paragraph (2).
(2)If the United States Food and Drug Administration has approved one or more therapeutic equivalents of a pangenotypic drug, device, or product for the treatment of hepatitis C, this section does not require a health care service plan to cover all of the therapeutically equivalent versions without prior authorization, if at least one pangenotypic and therapeutically equivalent version is covered without prior authorization.
(b)A health care service plans clinical criteria for hepatitis C treatment and prior authorization shall align with the current guidelines and the standard of care consistent with the standards of the American Association for the Study of Liver Diseases and the Infectious Diseases Society of America, and shall not impose prior authorization requirements, including, but not limited to, all of the following: Diseases and the Infectious Diseases Society of America or generally accepted clinical practice guidelines of another nonprofit health care provider professional association or specialty society pertaining to clinical hepatology or infectious disease. A plan shall not request, for the purpose of determining prior authorization for hepatitis C treatment, any of the following:
(1)A liver biopsy.
(2)Genotype testing.
(3)Sobriety requirements. Proof of sobriety.
(4)Fibrosis staging thresholds.
(5)Elastography or FibroScan documentation. Documentation of elastography or other measures of liver stiffness.
(6)Ultrasound documentation.
(7)A specialist referral or evaluation.
SEC. 2.Section 10123.1936 is added to the Insurance Code, to read:10123.1936.(a)(1)A health insurer shall not subject direct-acting antiviral drugs that are medically necessary for the treatment of hepatitis C, including, but not limited to, sofosbuvir/velpatasvir, sofosbuvir/ledipasvir, glecaprevir/pibrentasvir, or elbasvir/grazoprevir, C to prior authorization, except as provided in paragraph (2).
(2)If the United States Food and Drug Administration has approved one or more therapeutic equivalents of a pangenotypic drug, device, or product for the treatment of hepatitis C, this section does not require a health insurer to cover all of the therapeutically equivalent versions without prior authorization, if at least one pangenotypic and therapeutically equivalent version is covered without prior authorization.
(b)A health insurers clinical criteria for hepatitis C treatment and prior authorization shall align with the current guidelines and the standard of care consistent with the standards of the American Association for the Study of Liver Diseases and the Infectious Diseases Society of America, and shall not impose prior authorization requirements, including, but not limited to, all of the following: Diseases and the Infectious Diseases Society of America or generally accepted clinical practice guidelines of another nonprofit health care provider professional association or specialty society pertaining to clinical hepatology or infectious disease. An insurer shall not request, for the purpose of determining prior authorization for hepatitis C treatment, any of the following:
(1)A liver biopsy.
(2)Genotype testing.
(3)Sobriety requirements. Proof of sobriety.
(4)Fibrosis staging thresholds.
(5)Elastography or FibroScan documentation. Documentation of elastography or other measures of liver stiffness.
(6)Ultrasound documentation.
(7)A specialist referral or evaluation.
SEC. 3.No reimbursement is required by this act pursuant to Section 6 of Article XIIIB of the California Constitution because the only costs that may be incurred by a local agency or school district will be incurred because this act creates a new crime or infraction, eliminates a crime or infraction, or changes the penalty for a crime or infraction, within the meaning of Section 17556 of the Government Code, or changes the definition of a crime within the meaning of Section 6 of Article XIIIB of the California Constitution.
(a)(1)A health care service plan shall not subject direct-acting antiviral drugs that are medically necessary for the treatment of hepatitis C, including, but not limited to, sofosbuvir/velpatasvir, sofosbuvir/ledipasvir, glecaprevir/pibrentasvir, or elbasvir/grazoprevir, to prior authorization, except as provided in paragraph (2).
(2)If the United States Food and Drug Administration has approved one or more therapeutic equivalents of a drug, device, or product for the treatment of hepatitis C, this section does not require a health care service plan to cover all of the therapeutically equivalent versions without prior authorization, if at least one therapeutically equivalent version is covered without prior authorization.
(b)A health care service plans clinical criteria for hepatitis C treatment and prior authorization shall align with the current guidelines and the standard of care consistent with the standards of the American Liver Foundation and Association for the Study of Liver Diseases and the Infectious Diseases Society of America, and shall not impose prior authorization requirements, including, but not limited to, all of the following:
(1)A liver biopsy.
(2)Genotype testing.
(3)Sobriety requirements.
(4)Fibrosis staging thresholds.
(5)Elastography or FibroScan documentation.
(6)Ultrasound documentation.
(7)A specialist referral or evaluation.
SEC. 2.Section 121027 is added to the Health and Safety Code, to read:121027.(a)Public health records relating to hepatitis B and hepatitis C containing personally identifying information that were developed or acquired by local health agencies or their agents shall be confidential and shall not be disclosed except as otherwise provided by law or with the written consent of the individual who is the subject of the record or by the legal representative of the individual.(b)A local health officer may, for the purposes of case investigation and linkage to, or reengagement in care for, the person with hepatitis B or hepatitis C, may request and disclose without written consent of the individual any information, including personally identifying information, in hepatitis B and hepatitis C public health records from the persons health care provider or health care facilities as may be necessary to facilitate clinical management, treatment coordination, and the prevention of the spread of disease or occurrence of additional cases.(c)A local health officer, for the purposes of facilitating appropriate hepatitis B and hepatitis C medical care and treatment, may further disclose the information to the person positive for hepatitis B or hepatitis C who is the subject of the record, or the health care provider who provides the persons hepatitis care, for the purpose of proactively offering and coordinating care and treatment services. Any personally identifying information received pursuant to this subdivision by a health care provider or health care facility shall be confidential and shall not be further disclosed except as required by law or with the written consent of the individual.(d)Any disclosures authorized by subdivision (a), (b), or (c) shall include only the information necessary for the purpose of that disclosure and shall be made only upon the agreement that the information will be kept confidential as described in subdivision (a). Any unauthorized further disclosure shall be subject to the penalties described in subdivision (e).(e)(1)A person who negligently discloses the content of a confidential public health record to a third party, except pursuant to a written authorization, as described in subdivision (a), or as otherwise authorized by law, shall be subject to a civil penalty in an amount not to exceed five thousand dollars ($5,000), plus court costs, as determined by the court. The penalty and costs shall be paid to the person whose record was disclosed.(2)A person who willfully or maliciously discloses the content of any confidential public health record to a third party, except pursuant to a written authorization, or as otherwise authorized by law, shall be subject to a civil penalty in an amount not less than five thousand dollars ($5,000) and not more than twenty-five thousand dollars ($25,000), plus court costs, as determined by the court. The penalty and costs shall be paid to the person whose confidential public health record was disclosed.(3)A person who willfully, maliciously, or negligently discloses the content of a confidential public health record to a third party, except pursuant to a written authorization, or as otherwise authorized by law, that results in economic, bodily, or psychological harm to the person whose confidential public health record was disclosed, is guilty of a misdemeanor, punishable by imprisonment in a county jail for a period not to exceed one year, or a fine not to exceed twenty-five thousand dollars ($25,000), or both, plus court costs, as determined by the court. The penalty and costs shall be paid to the person whose confidential public health record was disclosed.(4)A person who commits an act described in paragraph (1), (2), or (3) is liable to the person whose confidential public health record was disclosed for all actual damages for economic, bodily, or psychological harm that is a proximate result of the act.(5)Each violation of this section is a separate and actionable offense.(6)This section does not limit or expand the right of an injured person whose confidential public health record was disclosed to recover damages under any other applicable law.(7)For the purposes of this section, a confidential public health record means the same as defined in subdivision (c) of Section 121035.SEC. 3.SEC. 2.Section 10123.1936 is added to the Insurance Code, to read:10123.1936.(a)(1)A health insurer shall not subject direct-acting antiviral drugs that are medically necessary for the treatment of hepatitis C, including, but not limited to, sofosbuvir/velpatasvir, sofosbuvir/ledipasvir, glecaprevir/pibrentasvir, or elbasvir/grazoprevir, to prior authorization, except as provided in paragraph (2).
(2)If the United States Food and Drug Administration has approved one or more therapeutic equivalents of a drug, device, or product for the treatment of hepatitis C, this section does not require a health insurer to cover all of the therapeutically equivalent versions without prior authorization, if at least one therapeutically equivalent version is covered without prior authorization.
(b)A health insurers clinical criteria for hepatitis C treatment and prior authorization shall align with the current guidelines and the standard of care consistent with the standards of the American Liver Foundation and Association for the Study of Liver Diseases and the Infectious Diseases Society of America, and shall not impose prior authorization requirements, including, but not limited to, all of the following:
(1)A liver biopsy.
(2)Genotype testing.
(3)Sobriety requirements.
(4)Fibrosis staging thresholds.
(5)Elastography or FibroScan documentation.
(6)Ultrasound documentation.
(7)A specialist referral or evaluation.
SEC. 4.The Legislature finds and declares that Section 2 of this act, which adds Section 121027 to the Health and Safety Code, imposes a limitation on the publics right of access to the meetings of public bodies or the writings of public officials and agencies within the meaning of Section 3 of Article I of the California Constitution. Pursuant to that constitutional provision, the Legislature makes the following findings to demonstrate the interest protected by this limitation and the need for protecting that interest:In order to protect confidential and personal medical information, it is necessary that the public health records relating to hepatitis B and hepatitis C, as described in this act, remain confidential.SEC. 5.SEC. 3.No reimbursement is required by this act pursuant to Section 6 of Article XIIIB of the California Constitution because the only costs that may be incurred by a local agency or school district will be incurred because this act creates a new crime or infraction, eliminates a crime or infraction, or changes the penalty for a crime or infraction, within the meaning of Section 17556 of the Government Code, or changes the definition of a crime within the meaning of Section 6 of Article XIIIB of the California Constitution.
(a)(1)A health care service plan shall not subject direct-acting antiviral drugs that are medically necessary for the treatment of hepatitis C, including, but not limited to, sofosbuvir/velpatasvir, sofosbuvir/ledipasvir, glecaprevir/pibrentasvir, or elbasvir/grazoprevir, to prior authorization, except as provided in paragraph (2).
(2)If the United States Food and Drug Administration has approved one or more therapeutic equivalents of a drug, device, or product for the treatment of hepatitis C, this section does not require a health care service plan to cover all of the therapeutically equivalent versions without prior authorization, if at least one therapeutically equivalent version is covered without prior authorization.
(b)A health care service plans clinical criteria for hepatitis C treatment and prior authorization shall align with the current guidelines and the standard of care consistent with the standards of the American Liver Foundation and Infectious Diseases Society of America, and shall not impose prior authorization requirements, including, but not limited to, all of the following:
(1)A liver biopsy.
(2)Genotype testing.
(3)Sobriety requirements.
(4)Fibrosis staging thresholds.
(5)Elastography or FibroScan documentation.
(6)Ultrasound documentation.
(7)A specialist referral or evaluation.
SEC. 2.Section 121027 is added to the Health and Safety Code, to read:121027.(a)Public health records relating to hepatitis B and hepatitis C containing personally identifying information that were developed or acquired by local health agencies or their agents shall be confidential and shall not be disclosed except as otherwise provided by law or with the written consent of the individual who is the subject of the record or by the legal representative of the individual.
(b)A local health officer may, for the purposes of case investigation and linkage to, or reengagement in care for, the person with hepatitis B or hepatitis C, may request and disclose without written consent of the individual any information, including personally identifying information, in hepatitis B and hepatitis C public health records from the persons health care provider or health care facilities as may be necessary to facilitate clinical management, treatment coordination, and the prevention of the spread of disease or occurrence of additional cases.
(c)A local health officer, for the purposes of facilitating appropriate hepatitis B and hepatitis C medical care and treatment, may further disclose the information to the person positive for hepatitis B or hepatitis C who is the subject of the record, or the health care provider who provides the persons hepatitis care, for the purpose of proactively offering and coordinating care and treatment services. Any personally identifying information received pursuant to this subdivision by a health care provider or health care facility shall be confidential and shall not be further disclosed except as required by law or with the written consent of the individual.
(d)Any disclosures authorized by subdivision (a), (b), or (c) shall include only the information necessary for the purpose of that disclosure and shall be made only upon the agreement that the information will be kept confidential as described in subdivision (a). Any unauthorized further disclosure shall be subject to the penalties described in subdivision (e).
(e)(1)A person who negligently discloses the content of a confidential public health record to a third party, except pursuant to a written authorization, as described in subdivision (a), or as otherwise authorized by law, shall be subject to a civil penalty in an amount not to exceed five thousand dollars ($5,000), plus court costs, as determined by the court. The penalty and costs shall be paid to the person whose record was disclosed.
(2)A person who willfully or maliciously discloses the content of any confidential public health record to a third party, except pursuant to a written authorization, or as otherwise authorized by law, shall be subject to a civil penalty in an amount not less than five thousand dollars ($5,000) and not more than twenty-five thousand dollars ($25,000), plus court costs, as determined by the court. The penalty and costs shall be paid to the person whose confidential public health record was disclosed.
(3)A person who willfully, maliciously, or negligently discloses the content of a confidential public health record to a third party, except pursuant to a written authorization, or as otherwise authorized by law, that results in economic, bodily, or psychological harm to the person whose confidential public health record was disclosed, is guilty of a misdemeanor, punishable by imprisonment in a county jail for a period not to exceed one year, or a fine not to exceed twenty-five thousand dollars ($25,000), or both, plus court costs, as determined by the court. The penalty and costs shall be paid to the person whose confidential public health record was disclosed.
(4)A person who commits an act described in paragraph (1), (2), or (3) is liable to the person whose confidential public health record was disclosed for all actual damages for economic, bodily, or psychological harm that is a proximate result of the act.
(5)Each violation of this section is a separate and actionable offense.
(6)This section does not limit or expand the right of an injured person whose confidential public health record was disclosed to recover damages under any other applicable law.
(7)For the purposes of this section, a confidential public health record means the same as defined in subdivision (c) of Section 121035.
SEC. 3.Section 10123.1936 is added to the Insurance Code, to read:10123.1936.(a)(1)A health insurer shall not subject direct-acting antiviral drugs that are medically necessary for the treatment of hepatitis C, including, but not limited to, sofosbuvir/velpatasvir, sofosbuvir/ledipasvir, glecaprevir/pibrentasvir, or elbasvir/grazoprevir, to prior authorization, except as provided in paragraph (2).
(2)If the United States Food and Drug Administration has approved one or more therapeutic equivalents of a drug, device, or product for the treatment of hepatitis C, this section does not require a health insurer to cover all of the therapeutically equivalent versions without prior authorization, if at least one therapeutically equivalent version is covered without prior authorization.
(b)A health insurers clinical criteria for hepatitis C treatment and prior authorization shall align with the current guidelines and the standard of care consistent with the standards of the American Liver Foundation and Infectious Diseases Society of America, and shall not impose prior authorization requirements, including, but not limited to, all of the following:
(1)A liver biopsy.
(2)Genotype testing.
(3)Sobriety requirements.
(4)Fibrosis staging thresholds.
(5)Elastography or FibroScan documentation.
(6)Ultrasound documentation.
(7)A specialist referral or evaluation.
SEC. 4.The Legislature finds and declares that Section 2 of this act, which adds Section 121027 to the Health and Safety Code, imposes a limitation on the publics right of access to the meetings of public bodies or the writings of public officials and agencies within the meaning of Section 3 of Article I of the California Constitution. Pursuant to that constitutional provision, the Legislature makes the following findings to demonstrate the interest protected by this limitation and the need for protecting that interest:
In order to protect confidential and personal medical information, it is necessary that the public health records relating to hepatitis B and hepatitis C, as described in this act, remain confidential.
SEC. 5.No reimbursement is required by this act pursuant to Section 6 of Article XIIIB of the California Constitution because the only costs that may be incurred by a local agency or school district will be incurred because this act creates a new crime or infraction, eliminates a crime or infraction, or changes the penalty for a crime or infraction, within the meaning of Section 17556 of the Government Code, or changes the definition of a crime within the meaning of Section 6 of Article XIIIB of the California Constitution.
|
Date
|
Status
|
|---|---|
| Sep 27, 2026 | Chaptered by Secretary of State - Chapter 552, Statutes of 2026. |
| Sep 27, 2026 | Approved by the Governor. |
| Sep 10, 2026 | Enrolled and presented to the Governor at 3 p.m. |
| Aug 30, 2026 | Senate amendments concurred in. To Engrossing and Enrolling. (Ayes 60. Noes 14. Page 6914.). |
| Aug 30, 2026 | Senate amendments concurred in. To Engrossing and Enrolling. (Ayes 60. Noes 14.). |
| Aug 30, 2026 | Senate amendments concurred in. To Engrossing and Enrolling. |
| Aug 30, 2026 | In Assembly. Concurrence in Senate amendments pending. |
| Aug 30, 2026 | Read third time. Passed. Ordered to the Assembly. (Ayes 30. Noes 8.). |
| Aug 27, 2026 | Read second time. Ordered to third reading. |
| Aug 26, 2026 | Read third time and amended. Ordered to second reading. |
| Aug 24, 2026 | Read second time. Ordered to third reading. |
| Aug 21, 2026 | Read third time and amended. Ordered to second reading. |
| Aug 4, 2026 | Read second time. Ordered to third reading. |
| Aug 3, 2026 | From committee: Be ordered to second reading pursuant to Senate Rule 28.8. |
| Jun 25, 2026 | From committee: Do pass and re-refer to Com. on APPR. (Ayes 8. Noes 1.) (June 24). Re-referred to Com. on APPR. |
| Jun 9, 2026 | In committee: Hearing postponed by committee. |
| Jun 8, 2026 | From committee chair, with author's amendments: Amend, and re-refer to committee. Read second time, amended, and re-referred to Com. on HEALTH. |
| Jun 3, 2026 | Referred to Com. on HEALTH. |
| May 21, 2026 | In Senate. Read first time. To Com. on RLS. for assignment. |
| May 21, 2026 | Read third time. Passed. Ordered to the Senate. (Ayes 57. Noes 13. Page 5178.) |
| May 21, 2026 | Read third time. Passed. Ordered to the Senate. (Ayes 57. Noes 13.) |
| May 7, 2026 | Read second time. Ordered to third reading. |
| May 6, 2026 | From committee: Do pass. (Ayes 10. Noes 2.) (May 6). |
| Apr 22, 2026 | From committee: Do pass and re-refer to Com. on APPR. (Ayes 12. Noes 2.) (April 21). Re-referred to Com. on APPR. |
| Mar 3, 2026 | Re-referred to Com. on HEALTH. |
| Mar 2, 2026 | From committee chair, with author's amendments: Amend, and re-refer to Com. on HEALTH. Read second time and amended. |
| Feb 23, 2026 | Referred to Coms. on HEALTH, P. & C.P. and JUD. |
| Feb 12, 2026 | From printer. May be heard in committee March 14. |
| Feb 11, 2026 | Read first time. To print. |
|
Date
|
Description
|
Location
|
Votes
|
|
|---|---|---|---|---|
| Aug 30, 2026 | AB 1843 Elhawary Concurrence in Senate Amendments | Assembly Floor |
Passed |
|
| Aug 30, 2026 | Assembly 3rd Reading AB1843 Elhawary By Wiener | Senate Floor |
Passed |
|
| Jun 24, 2026 | Do pass, but first be re-referred to the Committee on [Appropriations] | Senate Standing Committee on Health |
Passed |
|
| May 21, 2026 | AB 1843 Elhawary Assembly Third Reading | Assembly Floor |
Passed |
|
| May 6, 2026 | Do pass. | Assembly Standing Committee on Appropriations |
Passed |
|
| Apr 21, 2026 | Do pass and be re-referred to the Committee on [Appropriations] | Assembly Standing Committee on Health |
Passed |
This list shows positions taken on this bill by organizations on the date displayed, which is linked to the original source.
Positions by individuals are not included.
|
Organization
|
Position
|
Date
|
|---|---|---|
| Access Support Network | ** Support | |
| Aids Healthcare Foundation | ** Support | |
| American Academy of HIV Medicine California/Hawaii Steering Committee | ** Support | |
| APLA Health | ** Support | |
| Association Of California Life & Health Insurance Companies | ** Against | |
| Association of California Life Insurance Companies | ** Against | |
| Bartz-Altadonna Community Health Center | ** Support | |
| Beyond AIDS Foundation | ** Support | |
| Bienestar Human Services | ** Support | |
| California Academy of Preventive Medicine | ** Support | |
| California Association Of Health Plans | ** Against | |
| California & Hawai’i Chapter of the American Academy of HIV Medicine | ** Support | |
| California LGBTQ Health and Human Services Network | ** Support | |
| California Life Sciences Association | ** Support | |
| California Medical Association | ** Support | |
| California Small Business Association | ** Against | |
| California STD/HIV Controller's Association - Executive Committee | ** Support | |
| Community Health Project LA | ** Support | |
| Community Health Project Los Angeles | ** Support | |
| County Health Executives Association Of California | ** Support | |
| DAP Health | ** Support | |
| Drug Policy Alliance | ** Support | |
| End Hep C San Francisco (co-source) | ** Support | |
| end hep c sf | ** Support | |
| End HepC SF | ** Support | |
| Glide | ** Support | |
| Health Access California | ** Support | |
| Health Officers Association Of California | ** Support | |
| HealthRight 360 | ** Support | |
| Insurance Commissioner Ricardo Lara / California Department of Insurance | ** Support | |
| Kedren Community Health Center | ** Support | |
| Kedren Health | ** Support | |
| Liver Coalition of San Diego | ** Support | |
| National Health Law Program | ** Support | |
| One individual | ** Support | |
| San Francisco AIDS Foundation (co-source) | ** Support | |
| Sunburst Projects | ** Support |
CONCURRENCE IN SENATE AMENDMENTS
CSA1 Bill Id:AB 1843
Author:(Elhawary)
As Amended Ver:August 26, 2026
Majority vote
SUMMARY
Prohibits a health plan or health insurer from subjecting direct-acting antiviral drugs that are medically necessary for the treatment of hepatitis C to prior authorization (PA), as specified.
Senate Amendments
- Strike specific standards that health plans and insurers must align PA and clinical criteria with.
- Exempt Medi-Cal Managed Care Plans.
- Make technical and clarifying changes throughout the bill.
COMMENTS
Hepatitis C is a liver disease caused by infection from the hepatitis C virus (HCV), which is transmitted through exposure to infected blood or bodily fluids containing infected blood. Acute hepatitis C occurs within the first six months of exposure to HCV; chronic hepatitis C occurs if acute hepatitis C is not recognized and treated and the virus is not cleared by the body within 6 months. Studies estimate that acute hepatitis C leads to chronic infection in most patients. HCV is primarily transmitted by sharing contaminated needles, syringes, or other equipment used to prepare or inject drugs; other risk factors for transmission include multiple sexual partners, nonprofessional tattoo or piercing, prior incarceration, workplace exposure to needle sticks, or being born to an HCV-infected person. Individuals with hepatitis C can develop cirrhosis (advanced, irreversible scarring of the liver that leads to liver failure), liver cancer, and other liver- and non-liver–related complications and are at increased risk of premature death. Based on Department of Public Health data from 2018 (the most recent statewide surveillance data available), the annual rate of newly reported cases of chronic hepatitis C is estimated at 89 cases per 100,000 population in California (about 35,500 cases), which is a 10% decrease from 2017.
California Health Benefits Review Program (CHBRP). CHBRP was created in response to AB 1996 (Thomson), Chapter 795, Statutes of 2002, which requests the University of California to assess legislation proposing a mandated benefit or service and prepare a written analysis with relevant data on the medical, economic, and public health impacts of proposed health plan and health insurance benefit mandate legislation. SB 125 (Hernandez), Chapter 9, Statutes of 2015, added an impact assessment on essential health benefits (EHBs), and legislation that impacts health insurance benefit designs, cost-sharing, premiums, and other health insurance topics to CHBRP's purview. CHBRP reviewed this bill and included the following impact estimates in their analysis:
- Premium increases & enrollee out-of-pocket decreases. Premiums paid by employers and enrollees would increase upon enaction of this bill by an estimated $708,000 ($0.0020-$0.0134 per member per month). This premium increase applies to all enrollees regardless of whether they use the benefit. Aggregate cost sharing among enrollees who use direct-acting antiviral drugs would decrease by $40,000.
- Increased utilization of care. CHBRP estimates the treatment rate for enrollees diagnosed with hepatitis C would increase to 11%, leading to 34 additional enrollees receiving direct-acting antiviral drugs to treat hepatitis C. Of these newly treated enrollees, 95% are estimated to be cured, reducing average annual costs associated with clinical complications of untreated hepatitis C by $7,650 per enrollee.
- Medical effectiveness. CHBRP determined there is very strong evidence that direct-acting antiviral drugs are effective at treating hepatitis C, with cure rates above 95% for most medications. There is strong evidence that there is no difference in effectiveness among different direct-acting antiviral drugs. There is some evidence that removing prior authorization PA requirements leads to increased utilization of direct-acting antiviral drugs and not enough research to determine whether removing PA for direct-acting antiviral drugs improves health outcomes.
- Public health impacts. CHRBP determined that this bill would produce no measurable short-term public health impact at the population level due to the small estimated increase in utilization. However, this bill would likely yield health and quality-of-life improvements for the 34 additional enrollees using direct-acting antiviral drugs and the 342 enrollees avoiding pretreatment assessments no longer required under PA. Barriers related to cost sharing and access to screening and treatment may remain.
Utilization Management (UM) and Utilization Review (UR). UM and UR are processes used by health plans to evaluate and manage the use of health care services. UR can occur prospectively, retrospectively, or concurrently and a plan can approve, modify, delay or deny in whole or in part a request based on its medical necessity. PA is a UR technique used by health plans that requires patients to obtain approval of a service or medication before care is provided. PA is intended to allow plans to evaluate whether care that has been prescribed is medically necessary for purposes of coverage. PA is one type of UM tool that's used by health plans, along with others such as concurrent review and step therapy, to control costs, limit unnecessary care, and evaluate safety and appropriateness of a service.
Overall impact of PA. In 2023, CHBRP published a report to help the Legislature better understand the ways in which PA is used in California. CHBRP noted that PA is an imperfect instrument that is utilized in a myriad of ways. This poses a challenge for policymakers, payers, patients, and providers since PA is generally intended to decrease costs, but it may also contribute to delays in treatment and additional barriers to care. Currently, evidence is limited as to the extent to which health insurance uses PA and its impact on the performance of the health care system, patient access to appropriate care, and the health and financial interests of the general public. Despite the limited evidence, there is clear frustration from both patients and providers regarding PA practices. According to CHBRP, complaints range from the time required to complete the initial authorization request and pursue denials, to delays in care, to a general lack of transparency regarding the process and criteria used to evaluate PA requests. CHBRP further notes that people with disabilities, younger patients, African Americans, and people with lower incomes are more likely to report administrative burdens, including delays in care, due to PA.
Office of Health Care Affordability (OHCA) cost targets. OHCA was established in 2022 in response to widespread cost-related access challenges across California. According to the California Health Care Foundation (CHCF), over half of Californians say they skip or delay health care due to costs. OHCA collects, analyzes, and publicly reports data on total health care expenditures and enforces spending targets. OHCA's spending targets are intended to reduce excess spending and slow health care spending growth. In April of 2024, OHCA approved a statewide cost growth target of 3.5% starting in 2025 and phasing down to 3% by 2029. Health care entities, including health plans and insurers, are subject to the statewide spending target and are subject to progressive enforcement if the entity's costs exceed the target. Some entities have raised concerns that new legislative insurance mandates will make it difficult for them to meet the established cost growth target.
Current law does not explicitly require OHCA to adjust the cost growth targets based on changes to state policy, such as insurance mandates, that may increase spending. However, it does require OHCA to consider state benefit mandates in its development and enforcement of cost growth targets. Specifically, when establishing cost growth target methodology, OHCA is required to review relevant state policy changes impacting covered benefits, provider reimbursement, and costs, among other factors. In addition, in enforcing cost growth targets, OHCA is required to consider factors that contribute to spending in excess of the applicable target, and the extent to which each entity has control over the applicable components of its cost target.
According to the Author
Hepatitis C is a life-threatening disease that disproportionately affects marginalized communities if left untreated, but it is highly curable, with modern treatments curing over 95% of infections. The author continues that this bill ensures health plans follow current medical guidelines and eliminate extra requirements that are not medically necessary for accessing treatment. The author concludes that by streamlining access to care, this bill helps prevent serious health complications, reduces transmission, saves lives, reduces long-term healthcare costs, and moves California closer to eliminating hepatitis C.
Arguments in Support
End Hep C SF supports this bill, stating that reducing barriers to HCV treatment access is essential to achieving elimination and ensuring people can access timely, and life-saving care. End Hep C SF notes that based on the clinical guidelines in this bill and cost-effectiveness analyses, the Department of Health Care Services has in recent years eliminated from the Medi-Cal Rx formulary all potential barriers to treatment, including PA requirements. In contrast, End Hep C SF states that many commercial health insurers selling policies in California do impose PA requirements on treatment. In addition, as part of their PA processes, many of these insurers request information or procedures that are no longer required for treatment. End Hep C SF shares the example that some insurers ask for the "genotype" (i.e., distinct genetic strain) of the patient's HCV, but current medications treat all genotypes. End Hep C SF continues that others request liver biopsies, which are not recommended before HCV treatment–but are costly and dangerous. End Hep C SF argues that requiring PA for HCV medications and requesting unnecessary information or procedures as part of PA processes, often results in people with HCV not getting the treatment they need. End Hep C SF continues that the Legislature and Governor Newsom enacted SB 306 (Becker), Chapter 408, Statutes of 2025, in an effort to comprehensively reform PA. Unfortunately, End Hep C SF notes that bill does not apply to drugs in tier three or four of a health insurer's formulary, and current first-line treatments for HCV are all typically placed in those tiers. End Hep C SF argues that to solve the problem of PA for hepatitis C treatment, the Legislature must go one step further. End Hep C SF concludes that removing unneeded impediments to HCV treatment for Californians with commercial insurance—just as the state has done for Medi-Cal enrollees—will clear the way for people with HCV to get cured, lowering health care spending and bringing us closer to ending the HCV epidemic in the Golden State.
Arguments in Opposition
The California Association of Health Plans and Association of California Life Insurance Companies are opposed to this bill, stating that this bill can impact a plan's ability to manage healthcare spending at a time when healthcare spending is at an all time high. The opposition notes that just last year, the Legislature enacted SB 306 (Becker) establishing a comprehensive regulatory process to evaluate the use of prior authorization and determine which services and medications should be exempt from those requirements. The opposition continues that as part of that process, the Legislature specifically considered whether specialty drugs, particularly higher-cost Tier 3 and Tier 4 medications, should be exempt. Ultimately, the opposition notes that it was determined these medications should remain subject to prior authorization requirements. The opposition states that decision reflected the significant costs associated with many of these medications and the important role prior authorization can play in helping ensure enrollees receive clinically appropriate treatment at the lowest available cost. Additionally, the opposition notes that they are concerned with the provision of the bill that requires health plans/insurers to align their clinical criteria with the specific standards. The opposition argues that while guidelines can help establish the efficacy and safety of diagnostic testing or therapeutic interventions, codifying them into law is problematic because populations might differ and treatment evidence may evolve. Finally, the opposition continues to remain opposed to the high cost of prescription drugs, noting that cost of the drugs under this bill – which are a one time treatment – can be as high as $33,000. The opposition urges the Legislature, as they consider mandates that affect a health plan's/insurer's ability to manage costs, to take careful consideration of the significant costs associated with prescription drugs, which continue to be one of the primary drivers of health care spending.
FISCAL COMMENTS
According to the Senate Appropriations Committee, pursuant to Senate Rule 28.8, negligible state costs.
VOTES:
ASM HEALTH: 12-2-2
YES: Bonta, Addis, Aguiar-Curry, Ahrens, Caloza, Carrillo, Mark González, Patel, Rogers, Schiavo, Sharp-Collins, Stefani
NO: Johnson, Sanchez
ABS, ABST OR NV: Chen, Patterson
ASM APPROPRIATIONS: 10-2-3
YES: Wicks, Aguiar-Curry, Caloza, Fong, Mark González, Krell, Pacheco, Pellerin, Sharp-Collins, Solache
NO: Hoover, Tangipa
ABS, ABST OR NV: Arambula, Dixon, Ta
ASSEMBLY FLOOR: 57-13-10
YES: Addis, Aguiar-Curry, Ahrens, Alanis, Alvarez, Ávila Farías, Bains, Bauer-Kahan, Bennett, Berman, Boerner, Bonta, Bryan, Calderon, Caloza, Carrillo, Connolly, Elhawary, Fong, Gabriel, Gipson, Mark González, Haney, Harabedian, Hart, Irwin, Jackson, Kalra, Krell, Lee, Lowenthal, McKinnor, Muratsuchi, Nguyen, Ortega, Pacheco, Papan, Patel, Pellerin, Petrie-Norris, Quirk-Silva, Ransom, Michelle Rodriguez, Rogers, Blanca Rubio, Schiavo, Schultz, Sharp-Collins, Solache, Soria, Stefani, Valencia, Ward, Wicks, Wilson, Zbur, Rivas
NO: Castillo, Davies, DeMaio, Ellis, Flora, Gallagher, Hadwick, Hoover, Johnson, Macedo, Patterson, Sanchez, Tangipa
ABS, ABST OR NV: Arambula, Chen, Dixon, Garcia, Jeff Gonzalez, Lackey, Ramos, Celeste Rodriguez, Ta, Wallis
UPDATED
VERSION: August 26, 2026
CONSULTANT: Riana King / HEALTH / (916) 319-2097 FN: 0004116
SENATE RULES COMMITTEE Office of Senate Floor Analyses (916) 651-4171 | AB 1843 |
THIRD READING
Bill No: AB 1843
Author: Elhawary (D)
Amended: 8/21/26 in Senate
Vote: 21
SENATE HEALTH COMMITTEE: 8-1, 6/24/26
AYES: Weber Pierson, Caballero, Durazo, Gonzalez, Padilla, Pérez, Rubio, Smallwood-Cuevas
NOES: Grove
NO VOTE RECORDED: Valladares, Menjivar
SENATE APPROPRIATIONS COMMITTEE: Senate Rule 28.8
ASSEMBLY FLOOR: 57-13, 5/21/26 - See last page for vote
SUBJECT: Communicable diseases: hepatitis C
SOURCE: End Hep C San Francisco (co-source)
San Francisco AIDS Foundation (co-source)
DIGEST:
This bill prohibits health plans and insurers from subjecting direct-acting antiviral drugs that are medically necessary for the treatment of hepatitis C to prior authorization.
Senate Floor Amendments of 8/26/26 renumber a code section in order to avoid chaptering out conflicts with SB 1094 (Weber Pierson).
ANALYSIS:
Existing law:
- Establishes the Department of Managed Health Care (DMHC) to regulate health plans under the Knox-Keene Health Care Service Plan Act of 1975 and the California Department of Insurance (CDI) to regulate health insurers under the Insurance Code. [Health and Safety Code (HSC) §1340, et seq. and Insurance Code (INS) §106, et seq.]
- Prohibits health plans/insurers from subjecting antiretroviral drugs that are medically necessary for the prevention of AIDS/HIV, including preexposure prophylaxis (PrEP) and postexposure prophylaxis (PEP), to prior authorization or step therapy, except that if the U.S. Food and Drug Administration (FDA) approves one or more therapeutic equivalents of a drug, device, or product for the prevention of AIDS/HIV, in which case health plans/insurers are only required to cover at least one therapeutically equivalent version without prior authorization or step therapy. [HSC §1342.74(a) and INS §10123.1933(a)]
- Excludes, from health plan/insurer prior authorization requirements, health care services that have been approved by the plan/insurer 90% or more times, as determined by DMHC/CDI after evaluation of health plan and insurer reporting. This law does not apply to drugs that are on tier three or tier four of a health plan/insurer’s formulary, and sunsets on January 1, 2034. [HSC §1367.025(c)(4) and INS §10133.52(c)(4)]
This bill:
- Prohibits health plans/insurers from subjecting direct-acting antiviral (DAA) drugs, that are medically necessary for the treatment of hepatitis C, to prior authorization. Specifies that if the U.S. Food and Drug Administration (FDA) has approved one or more therapeutic equivalents of a pangenotypic drug, device, or product for the treatment of hepatitis C, this bill does not require a health plan/insurer to cover all of the therapeutically equivalent versions without prior authorization, if at least one pangenotypic and therapeutically equivalent version is covered without prior authorization.
- Requires health plan/insurers’ clinical criteria for hepatitis C treatment and prior authorization to align with the current guidelines and the standard of care consistent with the standards of the American Association for the Study of Liver Diseases and the Infectious Diseases Society of America (AASLD-IDSA), or generally accepted clinical practice guidelines of another nonprofit health care provider professional association, or specialty society pertaining to clinical hepatology or infectious disease.
- Exempts Medi-Cal managed care plans from this bill’s provisions.
Background
According to the author of this bill:
Hepatitis C is a life-threatening disease that disproportionately affects marginalized communities if left untreated, but it is highly curable, with modern treatments curing over 95% of infections. The author continues that this bill ensures health plans follow current medical guidelines and eliminate extra requirements that are not medically necessary for accessing treatment. The author concludes that by streamlining access to care, this bill helps prevent serious health complications, reduces transmission, saves lives, reduces long-term healthcare costs, and moves California closer to eliminating hepatitis C.
Hepatitis. Hepatitis C is a liver disease caused by infection from the hepatitis C virus (HCV), which is transmitted through exposure to infected blood or bodily fluids. According to the Centers for Disease Control and Prevention (CDC), acute hepatitis C occurs within the first six months of exposure to HCV; chronic hepatitis C occurs if acute hepatitis C is not recognized and treated and the virus is not cleared by the body within six months. According to the California Health Benefits Review Program (CHBRP) review of this bill, studies estimate that acute hepatitis C leads to chronic infection in most patients (80% to 85%). The majority of individuals with acute and chronic hepatitis C are asymptomatic, and evidence suggests that one-third of people with hepatitis C are unaware of their infection status and can unknowingly transmit the virus to others. Studies estimate that on average one person with HCV infection transmits the virus to one to four other people. HCV is primarily transmitted by sharing contaminated needles, syringes, or other equipment used to prepare or inject drugs; other risk factors for transmission include multiple sexual partners, nonprofessional tattoo or piercing, prior incarceration, workplace exposure to needle sticks, or being born to an HCV-infected woman. Individuals with hepatitis C can develop cirrhosis (advanced, irreversible scarring of the liver that leads to liver failure), liver cancer, and other liver- and non-liver-related complications and are at increased risk of premature death. Approximately two to four million people in the U.S. had hepatitis C. In 2023, the CDC found that there were 4,966 new reported cases of acute hepatitis C nationwide, but estimates new acute HCV infections at 69,000 after adjusting for underreporting. Based on California Department of Public Health data from 2018 (the most recent statewide surveillance data available), the annual rate of newly reported cases of chronic hepatitis C is estimated at 89 cases per 100,000 population in California (about 35,500 cases), which is a 10% decrease from 2017. According to 2023 CDC data, there were 11,194 deaths with hepatitis C listed as a cause of death in the U.S. (2.52 deaths per 100,000 population).
Hepatitis C screening and treatment. AASLD-IDSA, the CDC, and the U.S. Preventive Services Task Force recommend universal one-time HCV screening for adults aged 18 years and older. The purpose of antiviral treatment regimens for HCV infection is to prevent long-term health complications of chronic HCV infection. According to CHBRP, despite recommendations for universal HCV screening, studies have found delays in diagnosis and linkage to treatment for patients with HCV. A large national study published in the journal Digestive Diseases in September 2025 identified delayed diagnosis in 90% of patients with chronic hepatitis C, and 75% of patients experienced liver complications, despite availability of DAA treatment. This study also found that the majority of hepatitis C patients started DAA treatment after a liver complication had occurred, and only 6% of nondelayed diagnosis patients started DAA treatment more than two years before liver complications occurred. For individuals with HCV infection, the AASLD/IDSA guidelines include simplified HCV treatment algorithms for adults who have never been treated without cirrhosis. These simplified algorithms decrease requirements for pretreatment assessments for uncomplicated patients and are intended to be used by any health care provider knowledgeable about HCV treatment as long as they can consult a specialist if needed. The AASLD-IDSA guidelines recommend DAA treatment for all adults with acute or chronic HCV infection (except for individuals with short life expectancy). There are currently five DAA treatments available. Typical treatment duration is 8 to 12 weeks; some patients with decompensated cirrhosis receive treatment for 24 weeks. Three DAAs are pangenotypic (the treatments specified in this bill, applicable to any HCV genotype) and considered first-line treatment.
Although the guidelines continue to recommend interventions and lifestyle changes to prevent further liver damage, they no longer condition initiation of antiviral therapy on abstinence from alcohol or sobriety testing, genotype testing, or other tests for cirrhosis. According to CHBRP, as guidelines have continued to evolve, prior authorization requirements have not kept pace with updated guidelines by continuing to require pretreatment assessments. Pretreatment assessments commonly required as part of prior authorization requirements include those prohibited under this bill.
Prior authorization. Prior authorization is a form of utilization review or utilization management. California has a standardized form for prior authorization submissions. If a health plan or insurer fails to respond to the prior authorization request within 72 hours for nonurgent requests, and within 24 hours if exigent circumstances exist, upon the receipt of a completed form, the request is deemed granted. In 2023, at the request of the Legislature, CHBRP conducted a survey of California-regulated plans and insurers and found that overall, between 5% and 15% of all covered medical services, and between 16% and 25% of pharmacy benefits, were subject to prior authorization requirements. While there were significant differences among plans, some of the most frequently requested services and treatments were not necessarily the most expensive categories of treatments. Many under the medical benefit were services or treatment for ongoing care, such as behavioral health services and physical, occupational, or speech therapies. Some were rare or more expensive, but with low utilization rates.
SB 306 process. A growing number of bills have been introduced over the past ten years to remove health plan and insurer prior authorization requirements for a variety of health care services and treatments. Last year the Legislature passed, and the Governor signed, SB 306 (Becker, Chapter 408, Statutes of 2025), which will exempt health care services that have high approval rates (90% or higher) from prior authorization by health plans and insurers. During the debate over SB 306, supporters stated that insurance companies frequently use prior authorization as a cost-control tool, but that it often results in delays or denials of essential treatments for patients. SB 306 set up a process by which high-approval services do not require prior authorization. In July 2026, plans and insurers began reporting information to their regulators about prior authorization approval rates, and regulators are required to publish a list of services that receive prior authorization at least 90% of the time. Beginning January 1, 2028, health plans and insurers will cease requiring prior authorizations for services with high approval rates as identified by the regulators. DMHC/CDI are also required to publish a report regarding the impact of the cessation of prior authorization requirements and include data on the volume of covered health care services subjected to prior authorization, statistics on prior authorization requests and determinations, administrative costs, timely access to care, enrollee health outcomes, and data on reinstatements of prior authorization.
SB 306 allows health plans and insurers to continue prior authorizations on a variety of services, such as a novel application of existing therapy, services by an out-of-network or noncontracting provider, clear and convincing concerns about fraud or clinically inappropriate care, and services that are used differently from the use approved or cleared by the FDA. Additionally, outpatient drugs in Tier 3 or Tier 4 of a drug formulary are excluded from the SB 306 process. Tier 3 and Tier 4 drugs are defined in existing law as brand name drugs that generally have a preferred and less costly therapeutic alternative at a lower tier and specialty drugs. The drugs specified under this bill are Tier 3 and 4 drugs.
CHBRP report. AB 1996 (Thomson, Chapter 795, Statutes of 2002) requests the University of California to assess legislation proposing a mandated benefit or service and prepare a written analysis with relevant data on the medical, economic, and public health impacts of proposed health plan and health insurance benefit mandate legislation. CHBRP was created in response to AB 1996 and reviewed this bill. Key findings include:
- Benefit Coverage. Among the 13.2 million enrollees with a state-regulated pharmacy benefit, CHBRP estimates 5.7 million enrollees (43%) are in plans or policies out of compliance with this bill due to prior authorization requirements, and 7.5 million enrollees (57%) are in plans or policies that are compliant. This bill would not exceed essential health benefits.
- Medical Effectiveness. There is very strong evidence that DAAs are effective at treating hepatitis C, with cure rates above 95% for most medications. There is strong evidence that there is no difference in effectiveness among DAAs. There is some evidence that removing prior authorization requirements leads to increased utilization of DAAs and not enough research to determine whether removing prior authorization for DAAs improves health outcomes.
- Cost Impacts. Among the 3,423 enrollees with a state-regulated pharmacy benefit that included prior authorization requirements at baseline who are diagnosed with hepatitis C within the first year, approximately 10% (or 342 enrollees) would receive DAAs. Postmandate, these enrollees would avoid an estimated 924 pretreatment tests and services per year from the removal of prior authorization requirements, resulting in an annual estimated decrease of $346 in costs per enrollee. Furthermore, postmandate, CHBRP estimates the treatment rate for enrollees diagnosed with hepatitis C would increase to 11%, leading to 34 additional enrollees receiving DAAs to treat hepatitis C at a cost of $33,000 per course of treatment. Of these newly treated enrollees, 95% are estimated to be cured, reducing average annual costs associated with clinical complications of untreated hepatitis C by $7,650 per enrollee, resulting in the change in their expenses to range from a decrease of $895 to an increase of $644 depending on the market segment and plan design. Total annual premiums would increase by $708,000, paid by employers and enrollees ($0.0020-$0.0134 per member per month). This premium increase applies to all enrollees regardless of whether they use the benefit. Aggregate cost sharing among enrollees who use DAAs would decrease by $40,000.
- Public Health Impacts. CHBRP projects no measurable public health impact at the population level due to the small, estimated increase in utilization. However, this bill would likely yield health and quality-of-life improvements for the 34 additional enrollees using DAAs and the 342 enrollees avoiding pretreatment assessments no longer required under prior authorization. Barriers related to cost sharing and access to screening and treatment may remain.
- Long-Term Impacts. Recent updates to HCV treatment guidelines have expanded eligibility, decreased requirements for testing and monitoring, and emphasized that HCV treatment can often be managed by nonspecialist providers. Increased uptake of the recently updated guidelines in conjunction with the removal of prior authorization is likely to increase the number of nonspecialists prescribing DAA therapy for patients with HCV infection, thereby increasing access to treatment and cure.
FISCAL EFFECT: Appropriation: No Fiscal Com.: Yes Local: Yes
SUPPORT: (Verified 8/26/26)
End Hep C San Francisco (co-source)
San Francisco AIDS Foundation (co-source)
Access Support Network
AIDS Healthcare Foundation
APLA Health
Beyond AIDS Foundation
Bienestar Human Services
California Academy of Preventive Medicine
California & Hawai’i Chapter of the American Academy of HIV Medicine
California LGBTQ Health and Human Services Network
California Life Sciences Association
California Medical Association
Community Health Project Los Angeles
County Health Executives Association of California
DAP Health
Drug Policy Alliance
GLIDE
Health Access California
Health Officers Association of California
HealthRIGHT 360
Insurance Commissioner Ricardo Lara / California Department of Insurance
Kedren Community Health Center
Liver Coalition of San Diego
National Health Law Program
Sunburst Projects
OPPOSITION: (Verified 8/26/26)
Association of California Life & Health Insurance Companies
California Association of Health Plans
ARGUMENTS IN SUPPORT: San Francisco AIDS Foundation and End Hep C SF write that the definitive medical guidelines for hepatitis C treatment in the U.S., published by AASLD-IDSA, recommend timely treatment for almost all people living with HCV. The guidelines also note that treating hepatitis C is highly cost-effective. Treating hepatitis C saves the health care system money. This stands to reason: the cost of a single course of medication is much lower than the cost of treating a lifetime of complications like cirrhosis and liver failure (and the cost of treating one person with HCV is clearly lower than the cost of treating multiple people to whom the first person may otherwise transmit the virus). Supporters state that based on the AASLD-IDSA guidelines and cost-effectiveness analyses, the Department of Health Care Services has in recent years eliminated from the Medi-Cal Rx formulary all potential barriers to treatment, including prior-authorization requirements. In contrast, many commercial health insurers selling policies in California do impose prior authorization requirements on treatment. In addition, as part of their processes, many of these insurers request information or procedures that are no longer required for treatment. For example, some insurers ask for the “genotype” (i.e., distinct genetic strain) of the patient’s HCV, but current medications treat all genotypes (i.e., are “pangenotypic”). Others request liver biopsies, which are not recommended before HCV treatment–but are costly and dangerous. Requiring prior authorization for HCV medications and requesting unnecessary information or procedures as part of their processes, often results in people with HCV not getting the treatment they need. Both surveys of providers and analyses of patient data indicate that prior authorization causes delays in care, treatment abandonment, and ultimately worse health. Many people with HCV have a history of injection drug use and/or incarceration, so may face a high level of instability in their lives. This puts them at elevated risk of falling out of care due to barriers such as prior authorization. About two thirds of people who have private insurance and are diagnosed with HCV do not successfully initiate treatment within 360 days; prior authorization is one reason why.
ARGUMENTS IN OPPOSITION: The Association of California Life & Health Insurance Companies and California Association of Health Plans (ACLHIC/CAHP) writes that while they appreciate the intent of this bill, they oppose the provisions of the bill that would limit a health plan’s/insurer’s ability to conduct prior authorization. Just last year, the Legislature enacted SB 306, establishing a comprehensive regulatory process to evaluate the use of prior authorization and determine which services and medications should be exempt from those requirements. As part of that process, the Legislature specifically considered whether specialty drugs, particularly higher-cost Tier 3 and Tier 4 medications, should be exempt. Ultimately, they determined these medications should remain subject to prior authorization requirements. That decision reflected the significant costs associated with many of these medications and the important role prior authorization can play in helping ensure enrollees receive clinically appropriate treatment at the lowest available cost. By removing prior authorization requirements for certain drugs used to treat hepatitis C, this bill would deviate from the Legislature’s recent and deliberate policy decision to maintain utilization management safeguards for higher-cost specialty medications. Additionally, ACLHIC/CAHP remain concerned with the provision of the bill that would codify specific clinical criteria and treatment guidelines into statute. While clinical guidelines can help inform evidence-based care and establish the efficacy and safety of diagnostic tests or therapeutic interventions, codifying them into law is problematic because medical evidence and standards of care evolve over time. Guidelines are intended to support, not replace, individualized clinical decision-making, and patient needs may vary significantly from the populations on which the guidelines are based. As a result, statutory clinical requirements risk becoming outdated and may reduce the flexibility needed to incorporate new evidence and advances in care.
ASSEMBLY FLOOR: 57-13, 5/21/26
AYES: Addis, Aguiar-Curry, Ahrens, Alanis, Alvarez, Ávila Farías, Bains, Bauer-Kahan, Bennett, Berman, Boerner, Bonta, Bryan, Calderon, Caloza, Carrillo, Connolly, Elhawary, Fong, Gabriel, Gipson, Mark González, Haney, Harabedian, Hart, Irwin, Jackson, Kalra, Krell, Lee, Lowenthal, McKinnor, Muratsuchi, Nguyen, Ortega, Pacheco, Papan, Patel, Pellerin, Petrie-Norris, Quirk-Silva, Ransom, Michelle Rodriguez, Rogers, Blanca Rubio, Schiavo, Schultz, Sharp-Collins, Solache, Soria, Stefani, Valencia, Ward, Wicks, Wilson, Zbur, Rivas
NOES: Castillo, Davies, DeMaio, Ellis, Flora, Gallagher, Hadwick, Hoover, Johnson, Macedo, Patterson, Sanchez, Tangipa
NO VOTE RECORDED: Arambula, Chen, Dixon, Garcia, Jeff Gonzalez, Lackey, Ramos, Celeste Rodriguez, Ta, Wallis
Prepared by: Melanie Moreno / HEALTH / (916) 651-4111
8/27/26 22:09:24
**** END ****
SENATE RULES COMMITTEE Office of Senate Floor Analyses (916) 651-4171 | AB 1843 |
THIRD READING
Bill No: AB 1843
Author: Elhawary (D)
Amended: 8/21/26 in Senate
Vote: 21
SENATE HEALTH COMMITTEE: 8-1, 6/24/26
AYES: Weber Pierson, Caballero, Durazo, Gonzalez, Padilla, Pérez, Rubio, Smallwood-Cuevas
NOES: Grove
NO VOTE RECORDED: Valladares, Menjivar
SENATE APPROPRIATIONS COMMITTEE: Senate Rule 28.8
ASSEMBLY FLOOR: 57-13, 5/21/26 - See last page for vote
SUBJECT: Communicable diseases: hepatitis C
SOURCE: End Hep C San Francisco (co-source)
San Francisco AIDS Foundation (co-source)
DIGEST:
This bill prohibits health plans and insurers from subjecting direct-acting antiviral drugs that are medically necessary for the treatment of hepatitis C to prior authorization.
Senate Floor Amendments of 8/21/2026:
- Delete provisions that would have prohibited health plans/insurers, for the purpose of determining prior authorization for hepatitis C treatment, from requesting specified tests and documentation.
- Exclude Medi-Cal managed care plans from the bill’s requirements.
- Renumber a code section in order to avoid chaptering out conflicts with AB 1887 (Zbur).
ANALYSIS:
Existing law:
- Establishes the Department of Managed Health Care (DMHC) to regulate health plans under the Knox-Keene Health Care Service Plan Act of 1975 and the California Department of Insurance (CDI) to regulate health insurers under the Insurance Code. [Health and Safety Code (HSC) §1340, et seq. and Insurance Code (INS) §106, et seq.]
- Prohibits health plans/insurers from subjecting antiretroviral drugs that are medically necessary for the prevention of AIDS/HIV, including preexposure prophylaxis (PrEP) and postexposure prophylaxis (PEP), to prior authorization or step therapy, except that if the U.S. Food and Drug Administration (FDA) approves one or more therapeutic equivalents of a drug, device, or product for the prevention of AIDS/HIV, in which case health plans/insurers are only required to cover at least one therapeutically equivalent version without prior authorization or step therapy. [HSC §1342.74(a) and INS §10123.1933(a)]
- Excludes, from health plan/insurer prior authorization requirements, health care services that have been approved by the plan/insurer 90% or more times, as determined by DMHC/CDI after evaluation of health plan and insurer reporting. This law does not apply to drugs that are on tier three or tier four of a health plan/insurer’s formulary, and sunsets on January 1, 2034. [HSC §1367.025(c)(4) and INS §10133.52(c)(4)]
This bill:
- Prohibits health plans/insurers from subjecting direct-acting antiviral (DAA) drugs, that are medically necessary for the treatment of hepatitis C, to prior authorization. Specifies that if the FDA has approved one or more therapeutic equivalents of a pangenotypic drug, device, or product for the treatment of hepatitis C, this bill does not require a health plan/insurer to cover all of the therapeutically equivalent versions without prior authorization, if at least one pangenotypic and therapeutically equivalent version is covered without prior authorization.
- Requires health plan/insurers’ clinical criteria for hepatitis C treatment and prior authorization to align with the current guidelines and the standard of care consistent with the standards of the American Association for the Study of Liver Diseases and the Infectious Diseases Society of America (AASLD-IDSA), or generally accepted clinical practice guidelines of another nonprofit health care provider professional association, or specialty society pertaining to clinical hepatology or infectious disease.
- Exempts Medi-Cal managed care plans from this bill’s provisions.
Background
According to the author of this bill:
Hepatitis C is a life-threatening disease that disproportionately affects marginalized communities if left untreated, but it is highly curable, with modern treatments curing over 95% of infections. The author continues that this bill ensures health plans follow current medical guidelines and eliminate extra requirements that are not medically necessary for accessing treatment. The author concludes that by streamlining access to care, this bill helps prevent serious health complications, reduces transmission, saves lives, reduces long-term healthcare costs, and moves California closer to eliminating hepatitis C.
Hepatitis. Hepatitis C is a liver disease caused by infection from the hepatitis C virus (HCV), which is transmitted through exposure to infected blood or bodily fluids. According to the Centers for Disease Control and Prevention (CDC), acute hepatitis C occurs within the first six months of exposure to HCV; chronic hepatitis C occurs if acute hepatitis C is not recognized and treated and the virus is not cleared by the body within six months. According to the California Health Benefits Review Program (CHBRP) review of this bill, studies estimate that acute hepatitis C leads to chronic infection in most patients (80% to 85%). The majority of individuals with acute and chronic hepatitis C are asymptomatic, and evidence suggests that one-third of people with hepatitis C are unaware of their infection status and can unknowingly transmit the virus to others. Studies estimate that on average one person with HCV infection transmits the virus to one to four other people. HCV is primarily transmitted by sharing contaminated needles, syringes, or other equipment used to prepare or inject drugs; other risk factors for transmission include multiple sexual partners, nonprofessional tattoo or piercing, prior incarceration, workplace exposure to needle sticks, or being born to an HCV-infected woman. Individuals with hepatitis C can develop cirrhosis (advanced, irreversible scarring of the liver that leads to liver failure), liver cancer, and other liver- and non-liver-related complications and are at increased risk of premature death. Approximately two to four million people in the U.S. had hepatitis C. In 2023, the CDC found that there were 4,966 new reported cases of acute hepatitis C nationwide, but estimates new acute HCV infections at 69,000 after adjusting for underreporting. Based on California Department of Public Health data from 2018 (the most recent statewide surveillance data available), the annual rate of newly reported cases of chronic hepatitis C is estimated at 89 cases per 100,000 population in California (about 35,500 cases), which is a 10% decrease from 2017. According to 2023 CDC data, there were 11,194 deaths with hepatitis C listed as a cause of death in the U.S. (2.52 deaths per 100,000 population).
Hepatitis C screening and treatment. AASLD-IDSA, the CDC, and the U.S. Preventive Services Task Force recommend universal one-time HCV screening for adults aged 18 years and older. The purpose of antiviral treatment regimens for HCV infection is to prevent long-term health complications of chronic HCV infection. According to CHBRP, despite recommendations for universal HCV screening, studies have found delays in diagnosis and linkage to treatment for patients with HCV. A large national study published in the journal Digestive Diseases in September 2025 identified delayed diagnosis in 90% of patients with chronic hepatitis C, and 75% of patients experienced liver complications, despite availability of DAA treatment. This study also found that the majority of hepatitis C patients started DAA treatment after a liver complication had occurred, and only 6% of nondelayed diagnosis patients started DAA treatment more than two years before liver complications occurred. For individuals with HCV infection, the AASLD/IDSA guidelines include simplified HCV treatment algorithms for adults who have never been treated without cirrhosis. These simplified algorithms decrease requirements for pretreatment assessments for uncomplicated patients and are intended to be used by any health care provider knowledgeable about HCV treatment as long as they can consult a specialist if needed. The AASLD-IDSA guidelines recommend DAA treatment for all adults with acute or chronic HCV infection (except for individuals with short life expectancy). There are currently five DAA treatments available. Typical treatment duration is 8 to 12 weeks; some patients with decompensated cirrhosis receive treatment for 24 weeks. Three DAAs are pangenotypic (the treatments specified in this bill, applicable to any HCV genotype) and considered first-line treatment.
Although the guidelines continue to recommend interventions and lifestyle changes to prevent further liver damage, they no longer condition initiation of antiviral therapy on abstinence from alcohol or sobriety testing, genotype testing, or other tests for cirrhosis. According to CHBRP, as guidelines have continued to evolve, prior authorization requirements have not kept pace with updated guidelines by continuing to require pretreatment assessments. Pretreatment assessments commonly required as part of prior authorization requirements include those prohibited under this bill.
Prior authorization. Prior authorization is a form of utilization review or utilization management. California has a standardized form for prior authorization submissions. If a health plan or insurer fails to respond to the prior authorization request within 72 hours for nonurgent requests, and within 24 hours if exigent circumstances exist, upon the receipt of a completed form, the request is deemed granted. In 2023, at the request of the Legislature, CHBRP conducted a survey of California-regulated plans and insurers and found that overall, between 5% and 15% of all covered medical services, and between 16% and 25% of pharmacy benefits, were subject to prior authorization requirements. While there were significant differences among plans, some of the most frequently requested services and treatments were not necessarily the most expensive categories of treatments. Many under the medical benefit were services or treatment for ongoing care, such as behavioral health services and physical, occupational, or speech therapies. Some were rare or more expensive, but with low utilization rates.
SB 306 process. A growing number of bills have been introduced over the past ten years to remove health plan and insurer prior authorization requirements for a variety of health care services and treatments. Last year the Legislature passed, and the Governor signed, SB 306 (Becker, Chapter 408, Statutes of 2025), which will exempt health care services that have high approval rates (90% or higher) from prior authorization by health plans and insurers. During the debate over SB 306, supporters stated that insurance companies frequently use prior authorization as a cost-control tool, but that it often results in delays or denials of essential treatments for patients. SB 306 set up a process by which high-approval services do not require prior authorization. In July 2026, plans and insurers began reporting information to their regulators about prior authorization approval rates, and regulators are required to publish a list of services that receive prior authorization at least 90% of the time. Beginning January 1, 2028, health plans and insurers will cease requiring prior authorizations for services with high approval rates as identified by the regulators. DMHC/CDI are also required to publish a report regarding the impact of the cessation of prior authorization requirements and include data on the volume of covered health care services subjected to prior authorization, statistics on prior authorization requests and determinations, administrative costs, timely access to care, enrollee health outcomes, and data on reinstatements of prior authorization.
SB 306 allows health plans and insurers to continue prior authorizations on a variety of services, such as a novel application of existing therapy, services by an out-of-network or noncontracting provider, clear and convincing concerns about fraud or clinically inappropriate care, and services that are used differently from the use approved or cleared by the FDA. Additionally, outpatient drugs in Tier 3 or Tier 4 of a drug formulary are excluded from the SB 306 process. Tier 3 and Tier 4 drugs are defined in existing law as brand name drugs that generally have a preferred and less costly therapeutic alternative at a lower tier and specialty drugs. The drugs specified under this bill are Tier 3 and 4 drugs.
CHBRP report. AB 1996 (Thomson, Chapter 795, Statutes of 2002) requests the University of California to assess legislation proposing a mandated benefit or service and prepare a written analysis with relevant data on the medical, economic, and public health impacts of proposed health plan and health insurance benefit mandate legislation. CHBRP was created in response to AB 1996 and reviewed this bill. Key findings include:
- Benefit Coverage. Among the 13.2 million enrollees with a state-regulated pharmacy benefit, CHBRP estimates 5.7 million enrollees (43%) are in plans or policies out of compliance with this bill due to prior authorization requirements, and 7.5 million enrollees (57%) are in plans or policies that are compliant. This bill would not exceed essential health benefits.
- Medical Effectiveness. There is very strong evidence that DAAs are effective at treating hepatitis C, with cure rates above 95% for most medications. There is strong evidence that there is no difference in effectiveness among DAAs. There is some evidence that removing prior authorization requirements leads to increased utilization of DAAs and not enough research to determine whether removing prior authorization for DAAs improves health outcomes.
- Cost Impacts. Among the 3,423 enrollees with a state-regulated pharmacy benefit that included prior authorization requirements at baseline who are diagnosed with hepatitis C within the first year, approximately 10% (or 342 enrollees) would receive DAAs. Postmandate, these enrollees would avoid an estimated 924 pretreatment tests and services per year from the removal of prior authorization requirements, resulting in an annual estimated decrease of $346 in costs per enrollee. Furthermore, postmandate, CHBRP estimates the treatment rate for enrollees diagnosed with hepatitis C would increase to 11%, leading to 34 additional enrollees receiving DAAs to treat hepatitis C at a cost of $33,000 per course of treatment. Of these newly treated enrollees, 95% are estimated to be cured, reducing average annual costs associated with clinical complications of untreated hepatitis C by $7,650 per enrollee, resulting in the change in their expenses to range from a decrease of $895 to an increase of $644 depending on the market segment and plan design. Total annual premiums would increase by $708,000, paid by employers and enrollees ($0.0020-$0.0134 per member per month). This premium increase applies to all enrollees regardless of whether they use the benefit. Aggregate cost sharing among enrollees who use DAAs would decrease by $40,000.
- Public Health Impacts. CHBRP projects no measurable public health impact at the population level due to the small, estimated increase in utilization. However, this bill would likely yield health and quality-of-life improvements for the 34 additional enrollees using DAAs and the 342 enrollees avoiding pretreatment assessments no longer required under prior authorization. Barriers related to cost sharing and access to screening and treatment may remain.
- Long-Term Impacts. Recent updates to HCV treatment guidelines have expanded eligibility, decreased requirements for testing and monitoring, and emphasized that HCV treatment can often be managed by nonspecialist providers. Increased uptake of the recently updated guidelines in conjunction with the removal of prior authorization is likely to increase the number of nonspecialists prescribing DAA therapy for patients with HCV infection, thereby increasing access to treatment and cure.
FISCAL EFFECT: Appropriation: No Fiscal Com.: Yes Local: Yes
SUPPORT: (Verified 8/21/26)
End Hep C San Francisco (co-source)
San Francisco AIDS Foundation (co-source)
Access Support Network
AIDS Healthcare Foundation
APLA Health
Beyond AIDS Foundation
Bienestar Human Services
California Academy of Preventive Medicine
California & Hawai’i Chapter of the American Academy of HIV Medicine
California LGBTQ Health and Human Services Network
California Life Sciences Association
California Medical Association
Community Health Project Los Angeles
County Health Executives Association of California
DAP Health
Drug Policy Alliance
GLIDE
Health Access California
Health Officers Association of California
HealthRIGHT 360
Insurance Commissioner Ricardo Lara / California Department of Insurance
Kedren Community Health Center
Liver Coalition of San Diego
National Health Law Program
Sunburst Projects
OPPOSITION: (Verified 8/21/26)
Association of California Life & Health Insurance Companies
California Association of Health Plans
ARGUMENTS IN SUPPORT: San Francisco AIDS Foundation and End Hep C SF write that the definitive medical guidelines for hepatitis C treatment in the U.S., published by AASLD-IDSA, recommend timely treatment for almost all people living with HCV. The guidelines also note that treating hepatitis C is highly cost-effective. Treating hepatitis C saves the health care system money. This stands to reason: the cost of a single course of medication is much lower than the cost of treating a lifetime of complications like cirrhosis and liver failure (and the cost of treating one person with HCV is clearly lower than the cost of treating multiple people to whom the first person may otherwise transmit the virus). Supporters state that based on the AASLD-IDSA guidelines and cost-effectiveness analyses, the Department of Health Care Services has in recent years eliminated from the Medi-Cal Rx formulary all potential barriers to treatment, including prior-authorization requirements. In contrast, many commercial health insurers selling policies in California do impose prior authorization requirements on treatment. In addition, as part of their processes, many of these insurers request information or procedures that are no longer required for treatment. For example, some insurers ask for the “genotype” (i.e., distinct genetic strain) of the patient’s HCV, but current medications treat all genotypes (i.e., are “pangenotypic”). Others request liver biopsies, which are not recommended before HCV treatment–but are costly and dangerous. Requiring prior authorization for HCV medications and requesting unnecessary information or procedures as part of their processes, often results in people with HCV not getting the treatment they need. Both surveys of providers and analyses of patient data indicate that prior authorization causes delays in care, treatment abandonment, and ultimately worse health. Many people with HCV have a history of injection drug use and/or incarceration, so may face a high level of instability in their lives. This puts them at elevated risk of falling out of care due to barriers such as prior authorization. About two thirds of people who have private insurance and are diagnosed with HCV do not successfully initiate treatment within 360 days; prior authorization is one reason why.
ARGUMENTS IN OPPOSITION: The Association of California Life & Health Insurance Companies and California Association of Health Plans (ACLHIC/CAHP) writes that while they appreciate the intent of this bill, they oppose the provisions of the bill that would limit a health plan’s/insurer’s ability to conduct prior authorization. Just last year, the Legislature enacted SB 306, establishing a comprehensive regulatory process to evaluate the use of prior authorization and determine which services and medications should be exempt from those requirements. As part of that process, the Legislature specifically considered whether specialty drugs, particularly higher-cost Tier 3 and Tier 4 medications, should be exempt. Ultimately, they determined these medications should remain subject to prior authorization requirements. That decision reflected the significant costs associated with many of these medications and the important role prior authorization can play in helping ensure enrollees receive clinically appropriate treatment at the lowest available cost. By removing prior authorization requirements for certain drugs used to treat hepatitis C, this bill would deviate from the Legislature’s recent and deliberate policy decision to maintain utilization management safeguards for higher-cost specialty medications. Additionally, ACLHIC/CAHP remain concerned with the provision of the bill that would codify specific clinical criteria and treatment guidelines into statute. While clinical guidelines can help inform evidence-based care and establish the efficacy and safety of diagnostic tests or therapeutic interventions, codifying them into law is problematic because medical evidence and standards of care evolve over time. Guidelines are intended to support, not replace, individualized clinical decision-making, and patient needs may vary significantly from the populations on which the guidelines are based. As a result, statutory clinical requirements risk becoming outdated and may reduce the flexibility needed to incorporate new evidence and advances in care.
ASSEMBLY FLOOR: 57-13, 5/21/26
AYES: Addis, Aguiar-Curry, Ahrens, Alanis, Alvarez, Ávila Farías, Bains, Bauer-Kahan, Bennett, Berman, Boerner, Bonta, Bryan, Calderon, Caloza, Carrillo, Connolly, Elhawary, Fong, Gabriel, Gipson, Mark González, Haney, Harabedian, Hart, Irwin, Jackson, Kalra, Krell, Lee, Lowenthal, McKinnor, Muratsuchi, Nguyen, Ortega, Pacheco, Papan, Patel, Pellerin, Petrie-Norris, Quirk-Silva, Ransom, Michelle Rodriguez, Rogers, Blanca Rubio, Schiavo, Schultz, Sharp-Collins, Solache, Soria, Stefani, Valencia, Ward, Wicks, Wilson, Zbur, Rivas
NOES: Castillo, Davies, DeMaio, Ellis, Flora, Gallagher, Hadwick, Hoover, Johnson, Macedo, Patterson, Sanchez, Tangipa
NO VOTE RECORDED: Arambula, Chen, Dixon, Garcia, Jeff Gonzalez, Lackey, Ramos, Celeste Rodriguez, Ta, Wallis
Prepared by: Melanie Moreno / HEALTH / (916) 651-4111
8/24/26 13:46:34
**** END ****
SENATE RULES COMMITTEE Office of Senate Floor Analyses (916) 651-4171 | AB 1843 |
THIRD READING
Bill No: AB 1843
Author: Elhawary (D)
Amended: 6/8/26 in Senate
Vote: 21
SENATE HEALTH COMMITTEE: 8-1, 6/24/26
AYES: Weber Pierson, Caballero, Durazo, Gonzalez, Padilla, Pérez, Rubio, Smallwood-Cuevas
NOES: Grove
NO VOTE RECORDED: Valladares, Menjivar
ASSEMBLY FLOOR: 57-13, 5/21/26 - See last page for vote
SUBJECT: Communicable diseases: hepatitis C
SOURCE: End Hep C San Francisco (co-source)
San Francisco AIDS Foundation (co-source)
DIGEST:
This bill prohibits health plans and insurers from subjecting direct-acting antiviral drugs that are medically necessary for the treatment of hepatitis C to prior authorization.
ANALYSIS:
Existing law:
- Establishes the Department of Managed Health Care (DMHC) to regulate health plans under the Knox-Keene Health Care Service Plan Act of 1975 and the California Department of Insurance (CDI) to regulate health insurers under the Insurance Code. [Health and Safety Code (HSC) §1340, et seq. and Insurance Code (INS) §106, et seq.]
- Prohibits health plans/insurers from subjecting antiretroviral drugs that are medically necessary for the prevention of AIDS/HIV, including preexposure prophylaxis (PrEP) and postexposure prophylaxis (PEP), to prior authorization or step therapy, except that if the U.S. Food and Drug Administration (FDA) approves one or more therapeutic equivalents of a drug, device, or product for the prevention of AIDS/HIV, in which case health plans/insurers are only required to cover at least one therapeutically equivalent version without prior authorization or step therapy. [HSC §1342.74(a) and INS §10123.1933(a)]
- Excludes, from health plan/insurer prior authorization requirements, health care services that have been approved by the plan/insurer 90% or more times, as determined by DMHC/CDI after evaluation of health plan and insurer reporting. This law does not apply to drugs that are on tier three or tier four of a health plan/insurer’s formulary, and sunsets on January 1, 2034. [HSC §1367.025(c)(4) and INS §10133.52(c)(4)]
This bill:
- Prohibits health plans/insurers from subjecting direct-acting antiviral (DAA) drugs, that are medically necessary for the treatment of hepatitis C, to prior authorization. Specifies that if the FDA has approved one or more therapeutic equivalents of a pangenotypic drug, device, or product for the treatment of hepatitis C, this bill does not require a health plan/insurer to cover all of the therapeutically equivalent versions without prior authorization, if at least one pangenotypic and therapeutically equivalent version is covered without prior authorization.
- Requires health plan/insurers’ clinical criteria for hepatitis C treatment and prior authorization to align with the current guidelines and the standard of care consistent with the standards of the American Association for the Study of Liver Diseases and the Infectious Diseases Society of America (AASLD-IDSA), or generally accepted clinical practice guidelines of another nonprofit health care provider professional association, or specialty society pertaining to clinical hepatology or infectious disease.
- Prohibits health plans/insurers, for the purpose of determining prior authorization for hepatitis C treatment, from requesting:
- A liver biopsy;
- Genotype testing;
- Proof of sobriety;
- Fibrosis staging thresholds;
- Documentation of elastography or other measures of liver stiffness;
- Ultrasound documentation; or,
- A specialist referral or evaluation.
Background
According to the author of this bill:
Hepatitis C is a life-threatening disease that disproportionately affects marginalized communities if left untreated, but it is highly curable, with modern treatments curing over 95% of infections. The author continues that this bill ensures health plans follow current medical guidelines and eliminate extra requirements that are not medically necessary for accessing treatment. The author concludes that by streamlining access to care, this bill helps prevent serious health complications, reduces transmission, saves lives, reduces long-term healthcare costs, and moves California closer to eliminating hepatitis C.
Hepatitis. Hepatitis C is a liver disease caused by infection from the hepatitis C virus (HCV), which is transmitted through exposure to infected blood or bodily fluids. According to the Centers for Disease Control and Prevention (CDC), acute hepatitis C occurs within the first six months of exposure to HCV; chronic hepatitis C occurs if acute hepatitis C is not recognized and treated and the virus is not cleared by the body within six months. According to the California Health Benefits Review Program (CHBRP) review of this bill, studies estimate that acute hepatitis C leads to chronic infection in most patients (80% to 85%). The majority of individuals with acute and chronic hepatitis C are asymptomatic, and evidence suggests that one-third of people with hepatitis C are unaware of their infection status and can unknowingly transmit the virus to others. Studies estimate that on average one person with HCV infection transmits the virus to one to four other people. HCV is primarily transmitted by sharing contaminated needles, syringes, or other equipment used to prepare or inject drugs; other risk factors for transmission include multiple sexual partners, nonprofessional tattoo or piercing, prior incarceration, workplace exposure to needle sticks, or being born to an HCV-infected woman. Individuals with hepatitis C can develop cirrhosis (advanced, irreversible scarring of the liver that leads to liver failure), liver cancer, and other liver- and non-liver-related complications and are at increased risk of premature death. Approximately two to four million people in the U.S. had hepatitis C. In 2023, the CDC found that there were 4,966 new reported cases of acute hepatitis C nationwide, but estimates new acute HCV infections at 69,000 after adjusting for underreporting. Based on California Department of Public Health data from 2018 (the most recent statewide surveillance data available), the annual rate of newly reported cases of chronic hepatitis C is estimated at 89 cases per 100,000 population in California (about 35,500 cases), which is a 10% decrease from 2017. According to 2023 CDC data, there were 11,194 deaths with hepatitis C listed as a cause of death in the U.S. (2.52 deaths per 100,000 population).
Hepatitis C screening and treatment. AASLD-IDSA, the CDC, and the U.S. Preventive Services Task Force recommend universal one-time HCV screening for adults aged 18 years and older. The purpose of antiviral treatment regimens for HCV infection is to prevent long-term health complications of chronic HCV infection. According to CHBRP, despite recommendations for universal HCV screening, studies have found delays in diagnosis and linkage to treatment for patients with HCV. A large national study published in the journal Digestive Diseases in September 2025 identified delayed diagnosis in 90% of patients with chronic hepatitis C, and 75% of patients experienced liver complications, despite availability of DAA treatment. This study also found that the majority of hepatitis C patients started DAA treatment after a liver complication had occurred, and only 6% of nondelayed diagnosis patients started DAA treatment more than two years before liver complications occurred. For individuals with HCV infection, the AASLD/IDSA guidelines include simplified HCV treatment algorithms for adults who have never been treated without cirrhosis. These simplified algorithms decrease requirements for pretreatment assessments for uncomplicated patients and are intended to be used by any health care provider knowledgeable about HCV treatment as long as they can consult a specialist if needed. The AASLD-IDSA guidelines recommend DAA treatment for all adults with acute or chronic HCV infection (except for individuals with short life expectancy). There are currently five DAA treatments available. Typical treatment duration is 8 to 12 weeks; some patients with decompensated cirrhosis receive treatment for 24 weeks. Three DAAs are pangenotypic (the treatments specified in this bill, applicable to any HCV genotype) and considered first-line treatment.
Although the guidelines continue to recommend interventions and lifestyle changes to prevent further liver damage, they no longer condition initiation of antiviral therapy on abstinence from alcohol or sobriety testing, genotype testing, or other tests for cirrhosis. According to CHBRP, as guidelines have continued to evolve, prior authorization requirements have not kept pace with updated guidelines by continuing to require pretreatment assessments. Pretreatment assessments commonly required as part of prior authorization requirements include those prohibited under this bill.
Prior authorization. Prior authorization is a form of utilization review or utilization management. California has a standardized form for prior authorization submissions. If a health plan or insurer fails to respond to the prior authorization request within 72 hours for nonurgent requests, and within 24 hours if exigent circumstances exist, upon the receipt of a completed form, the request is deemed granted. In 2023, at the request of the Legislature, CHBRP conducted a survey of California-regulated plans and insurers and found that overall, between 5% and 15% of all covered medical services, and between 16% and 25% of pharmacy benefits, were subject to prior authorization requirements. While there were significant differences among plans, some of the most frequently requested services and treatments were not necessarily the most expensive categories of treatments. Many under the medical benefit were services or treatment for ongoing care, such as behavioral health services and physical, occupational, or speech therapies. Some were rare or more expensive, but with low utilization rates.
SB 306 process. A growing number of bills have been introduced over the past ten years to remove health plan and insurer prior authorization requirements for a variety of health care services and treatments. Last year the Legislature passed, and the Governor signed, SB 306 (Becker, Chapter 408, Statutes of 2025), which will exempt health care services that have high approval rates (90% or higher) from prior authorization by health plans and insurers. During the debate over SB 306, supporters stated that insurance companies frequently use prior authorization as a cost-control tool, but that it often results in delays or denials of essential treatments for patients. SB 306 set up a process by which high-approval services do not require prior authorization. In July 2026, plans and insurers began reporting information to their regulators about prior authorization approval rates, and regulators are required to publish a list of services that receive prior authorization at least 90% of the time. Beginning January 1, 2028, health plans and insurers will cease requiring prior authorizations for services with high approval rates as identified by the regulators. DMHC/CDI are also required to publish a report regarding the impact of the cessation of prior authorization requirements and include data on the volume of covered health care services subjected to prior authorization, statistics on prior authorization requests and determinations, administrative costs, timely access to care, enrollee health outcomes, and data on reinstatements of prior authorization.
SB 306 allows health plans and insurers to continue prior authorizations on a variety of services, such as a novel application of existing therapy, services by an out-of-network or noncontracting provider, clear and convincing concerns about fraud or clinically inappropriate care, and services that are used differently from the use approved or cleared by the FDA. Additionally, outpatient drugs in Tier 3 or Tier 4 of a drug formulary are excluded from the SB 306 process. Tier 3 and Tier 4 drugs are defined in existing law as brand name drugs that generally have a preferred and less costly therapeutic alternative at a lower tier and specialty drugs. The drugs specified under this bill are Tier 3 and 4 drugs.
CHBRP report. AB 1996 (Thomson, Chapter 795, Statutes of 2002) requests the University of California to assess legislation proposing a mandated benefit or service and prepare a written analysis with relevant data on the medical, economic, and public health impacts of proposed health plan and health insurance benefit mandate legislation. CHBRP was created in response to AB 1996 and reviewed this bill. Key findings include:
- Benefit Coverage. Among the 13.2 million enrollees with a state-regulated pharmacy benefit, CHBRP estimates 5.7 million enrollees (43%) are in plans or policies out of compliance with this bill due to prior authorization requirements, and 7.5 million enrollees (57%) are in plans or policies that are compliant. This bill would not exceed essential health benefits.
- Medical Effectiveness. There is very strong evidence that DAAs are effective at treating hepatitis C, with cure rates above 95% for most medications. There is strong evidence that there is no difference in effectiveness among DAAs. There is some evidence that removing prior authorization requirements leads to increased utilization of DAAs and not enough research to determine whether removing prior authorization for DAAs improves health outcomes.
- Cost Impacts. Among the 3,423 enrollees with a state-regulated pharmacy benefit that included prior authorization requirements at baseline who are diagnosed with hepatitis C within the first year, approximately 10% (or 342 enrollees) would receive DAAs. Postmandate, these enrollees would avoid an estimated 924 pretreatment tests and services per year from the removal of prior authorization requirements, resulting in an annual estimated decrease of $346 in costs per enrollee. Furthermore, postmandate, CHBRP estimates the treatment rate for enrollees diagnosed with hepatitis C would increase to 11%, leading to 34 additional enrollees receiving DAAs to treat hepatitis C at a cost of $33,000 per course of treatment. Of these newly treated enrollees, 95% are estimated to be cured, reducing average annual costs associated with clinical complications of untreated hepatitis C by $7,650 per enrollee, resulting in the change in their expenses to range from a decrease of $895 to an increase of $644 depending on the market segment and plan design. Total annual premiums would increase by $708,000, paid by employers and enrollees ($0.0020-$0.0134 per member per month). This premium increase applies to all enrollees regardless of whether they use the benefit. Aggregate cost sharing among enrollees who use DAAs would decrease by $40,000.
- Public Health Impacts. CHBRP projects no measurable public health impact at the population level due to the small, estimated increase in utilization. However, this bill would likely yield health and quality-of-life improvements for the 34 additional enrollees using DAAs and the 342 enrollees avoiding pretreatment assessments no longer required under prior authorization. Barriers related to cost sharing and access to screening and treatment may remain.
- Long-Term Impacts. Recent updates to HCV treatment guidelines have expanded eligibility, decreased requirements for testing and monitoring, and emphasized that HCV treatment can often be managed by nonspecialist providers. Increased uptake of the recently updated guidelines in conjunction with the removal of prior authorization is likely to increase the number of nonspecialists prescribing DAA therapy for patients with HCV infection, thereby increasing access to treatment and cure.
FISCAL EFFECT: Appropriation: No Fiscal Com.: Yes Local: Yes
SUPPORT: (Verified 8/3/26)
End Hep C San Francisco (co-source)
San Francisco AIDS Foundation (co-source)
Access Support Network
AIDS Healthcare Foundation
APLA Health
Beyond AIDS Foundation
Bienestar Human Services
California Academy of Preventive Medicine
California & Hawai’i Chapter of the American Academy of HIV Medicine
California LGBTQ Health and Human Services Network
California Life Sciences Association
California Medical Association
Community Health Project Los Angeles
County Health Executives Association of California
DAP Health
Drug Policy Alliance
GLIDE
Health Access California
Health Officers Association of California
HealthRIGHT 360
Insurance Commissioner Ricardo Lara / California Department of Insurance
Kedren Community Health Center
Liver Coalition of San Diego
National Health Law Program
Sunburst Projects
OPPOSITION: (Verified 8/3/26)
Association of California Life & Health Insurance Companies
California Association of Health Plans
ARGUMENTS IN SUPPORT: San Francisco AIDS Foundation and End Hep C SF write that the definitive medical guidelines for hepatitis C treatment in the U.S., published by AASLD-IDSA, recommend timely treatment for almost all people living with HCV. The guidelines also note that treating hepatitis C is highly cost-effective. Treating hepatitis C saves the health care system money. This stands to reason: the cost of a single course of medication is much lower than the cost of treating a lifetime of complications like cirrhosis and liver failure (and the cost of treating one person with HCV is clearly lower than the cost of treating multiple people to whom the first person may otherwise transmit the virus). Supporters state that based on the AASLD-IDSA guidelines and cost-effectiveness analyses, the Department of Health Care Services has in recent years eliminated from the Medi-Cal Rx formulary all potential barriers to treatment, including prior-authorization requirements. In contrast, many commercial health insurers selling policies in California do impose prior authorization requirements on treatment. In addition, as part of their processes, many of these insurers request information or procedures that are no longer required for treatment. For example, some insurers ask for the “genotype” (i.e., distinct genetic strain) of the patient’s HCV, but current medications treat all genotypes (i.e., are “pangenotypic”). Others request liver biopsies, which are not recommended before HCV treatment–but are costly and dangerous. Requiring prior authorization for HCV medications and requesting unnecessary information or procedures as part of their processes, often results in people with HCV not getting the treatment they need. Both surveys of providers and analyses of patient data indicate that prior authorization causes delays in care, treatment abandonment, and ultimately worse health. Many people with HCV have a history of injection drug use and/or incarceration, so may face a high level of instability in their lives. This puts them at elevated risk of falling out of care due to barriers such as prior authorization. About two thirds of people who have private insurance and are diagnosed with HCV do not successfully initiate treatment within 360 days; prior authorization is one reason why.
ARGUMENTS IN OPPOSITION: The Association of California Life & Health Insurance Companies and California Association of Health Plans (ACLHIC/CAHP) writes that while they appreciate the intent of this bill, they oppose the provisions of the bill that would limit a health plan’s/insurer’s ability to conduct prior authorization. Just last year, the Legislature enacted SB 306, establishing a comprehensive regulatory process to evaluate the use of prior authorization and determine which services and medications should be exempt from those requirements. As part of that process, the Legislature specifically considered whether specialty drugs, particularly higher-cost Tier 3 and Tier 4 medications, should be exempt. Ultimately, they determined these medications should remain subject to prior authorization requirements. That decision reflected the significant costs associated with many of these medications and the important role prior authorization can play in helping ensure enrollees receive clinically appropriate treatment at the lowest available cost. By removing prior authorization requirements for certain drugs used to treat hepatitis C, this bill would deviate from the Legislature’s recent and deliberate policy decision to maintain utilization management safeguards for higher-cost specialty medications. Additionally, ACLHIC/CAHP remain concerned with the provision of the bill that would codify specific clinical criteria and treatment guidelines into statute. While clinical guidelines can help inform evidence-based care and establish the efficacy and safety of diagnostic tests or therapeutic interventions, codifying them into law is problematic because medical evidence and standards of care evolve over time. Guidelines are intended to support, not replace, individualized clinical decision-making, and patient needs may vary significantly from the populations on which the guidelines are based. As a result, statutory clinical requirements risk becoming outdated and may reduce the flexibility needed to incorporate new evidence and advances in care.
ASSEMBLY FLOOR: 57-13, 5/21/26
AYES: Addis, Aguiar-Curry, Ahrens, Alanis, Alvarez, Ávila Farías, Bains, Bauer-Kahan, Bennett, Berman, Boerner, Bonta, Bryan, Calderon, Caloza, Carrillo, Connolly, Elhawary, Fong, Gabriel, Gipson, Mark González, Haney, Harabedian, Hart, Irwin, Jackson, Kalra, Krell, Lee, Lowenthal, McKinnor, Muratsuchi, Nguyen, Ortega, Pacheco, Papan, Patel, Pellerin, Petrie-Norris, Quirk-Silva, Ransom, Michelle Rodriguez, Rogers, Blanca Rubio, Schiavo, Schultz, Sharp-Collins, Solache, Soria, Stefani, Valencia, Ward, Wicks, Wilson, Zbur, Rivas
NOES: Castillo, Davies, DeMaio, Ellis, Flora, Gallagher, Hadwick, Hoover, Johnson, Macedo, Patterson, Sanchez, Tangipa
NO VOTE RECORDED: Arambula, Chen, Dixon, Garcia, Jeff Gonzalez, Lackey, Ramos, Celeste Rodriguez, Ta, Wallis
Prepared by: Melanie Moreno / HEALTH / (916) 651-4111
8/5/26 15:04:20
SENATE COMMITTEE ON HEALTH
Senator Akilah Weber Pierson, Chair
BILL NO: AB 1843
AUTHOR: | Elhawary | ||
VERSION: | June 8, 2026 | ||
HEARING DATE: | June 24, 2026 | ||
CONSULTANT: | Melanie Moreno | ||
SUBJECT: Communicable diseases: hepatitis C
SUMMARY:
Prohibits health plans and insurers from subjecting direct-acting antiviral drugs that are medically necessary for the treatment of hepatitis C to prior authorization.
Existing law:
- Establishes the Department of Managed Health Care (DMHC) to regulate health plans under the Knox-Keene Health Care Service Plan Act of 1975 and the California Department of Insurance (CDI) to regulate health insurers under the Insurance Code. [HSC §1340, et seq. and INS §106, et seq.]
- Prohibits health plans/insurers from subjecting antiretroviral drugs that are medically necessary for the prevention of AIDS/HIV, including preexposure prophylaxis (PrEP) and postexposure prophylaxis (PEP), to prior authorization or step therapy, except that if the U.S. Food and Drug Administration (FDA) approves one or more therapeutic equivalents of a drug, device, or product for the prevention of AIDS/HIV, in which case health plans/insurers are only required to cover at least one therapeutically equivalent version without prior authorization or step therapy. [HSC §1342.74(a) and INS §10123.1933(a)]
- Excludes, from health plan/insurer prior authorization requirements, health care services that have been approved by the plan/insurer 90% or more times, as determined by DMHC/CDI after evaluation of health plan and insurer reporting. This law does not apply to drugs that are on tier three or tier four of a health plan/insurer’s formulary, and sunsets on January 1, 2034. [HSC §1367.025(c)(4) and INS §10133.52(c)(4)]
This bill:
- Prohibits health plans/insurers from subjecting direct-acting antiviral (DAA) drugs, that are medically necessary for the treatment of hepatitis C, to prior authorization. Specifies that if the FDA has approved one or more therapeutic equivalents of a pangenotypic drug, device, or product for the treatment of hepatitis C, this bill does not require a health plan/insurer to cover all of the therapeutically equivalent versions without prior authorization, if at least one pangenotypic and therapeutically equivalent version is covered without prior authorization.
- Requires health plan/insurers’ clinical criteria for hepatitis C treatment and prior authorization to align with the current guidelines and the standard of care consistent with the standards of the American Association for the Study of Liver Diseases and the Infectious Diseases Society of America (AASLD-IDSA), or generally accepted clinical practice guidelines of another nonprofit health care provider professional association, or specialty society pertaining to clinical hepatology or infectious disease.
- Prohibits health plans/insurers, for the purpose of determining prior authorization for hepatitis C treatment, from requesting:
- A liver biopsy;
- Genotype testing;
- Proof of sobriety;
- Fibrosis staging thresholds;
- Documentation of elastography or other measures of liver stiffness;
- Ultrasound documentation; or,
- A specialist referral or evaluation.
FISCAL EFFECT:
According to the Assembly Committee on Appropriations:
Costs to CDI of $7,000 in fiscal year (FY) 2026-27 and $19,000 in FY 2027-28 to review forms for compliance (Insurance Fund). DMHC anticipates minor and absorbable costs. California Health Benefits Review Program (CHBRP) estimates this bill would increase premiums for DMHC-regulated plans in the California Public Employees Retirement System (CalPERS) by $38,000, of which about $18,000 would be state General Fund costs. There would be additional General Fund costs for the CDI-regulated CalPERS insurance policies, possibly around $10,000.
No costs to the Medi-Cal program.
PRIOR VOTES:
Assembly Floor: | 57 - 13 |
Assembly Appropriations Committee: | 10 - 2 |
Assembly Health Committee: | 12 - 2 |
COMMENTS:
- Author’s statement. According to the author, hepatitis C is a life-threatening disease that disproportionately affects marginalized communities if left untreated, but it is highly curable, with modern treatments curing over 95% of infections. The author continues that this bill ensures health plans follow current medical guidelines and eliminate extra requirements that are not medically necessary for accessing treatment. The author concludes that by streamlining access to care, this bill helps prevent serious health complications, reduces transmission, saves lives, reduces long-term healthcare costs, and moves California closer to eliminating hepatitis C.
- Hepatitis. Hepatitis C is a liver disease caused by infection from the hepatitis C virus (HCV), which is transmitted through exposure to infected blood or bodily fluids. According to the Centers for Disease Control and Prevention (CDC), acute hepatitis C occurs within the first six months of exposure to HCV; chronic hepatitis C occurs if acute hepatitis C is not recognized and treated and the virus is not cleared by the body within six months. According to the CHBRP review of this bill, studies estimate that acute hepatitis C leads to chronic infection in most patients (80% to 85%). The majority of individuals with acute and chronic hepatitis C are asymptomatic, and evidence suggests that one-third of people with hepatitis C are unaware of their infection status and can unknowingly transmit the virus to others. Studies estimate that on average one person with HCV infection transmits the virus to one to four other people. HCV is primarily transmitted by sharing contaminated needles, syringes, or other equipment used to prepare or inject drugs; other risk factors for transmission include multiple sexual partners, nonprofessional tattoo or piercing, prior incarceration, workplace exposure to needle sticks, or being born to an HCV-infected woman. Individuals with hepatitis C can develop cirrhosis (advanced, irreversible scarring of the liver that leads to liver failure), liver cancer, and other liver- and non-liver-related complications and are at increased risk of premature death. Approximately two to four million people in the U.S. had hepatitis C. In 2023, the CDC found that there were 4,966 new reported cases of acute hepatitis C nationwide, but estimates new acute HCV infections at 69,000 after adjusting for underreporting. Based on California Department of Public Health data from 2018 (the most recent statewide surveillance data available), the annual rate of newly reported cases of chronic hepatitis C is estimated at 89 cases per 100,000 population in California (about 35,500 cases), which is a 10% decrease from 2017. According to 2023 CDC data, there were 11,194 deaths with hepatitis C listed as a cause of death in the U.S. (2.52 deaths per 100,000 population).
- Hepatitis C screening and treatment. AASLD-IDSA, the CDC, and the U.S. Preventive Services Task Force recommend universal one-time HCV screening for adults aged 18 years and older. The purpose of antiviral treatment regimens for HCV infection is to prevent long-term health complications of chronic HCV infection. According to CHBRP, despite recommendations for universal HCV screening, studies have found delays in diagnosis and linkage to treatment for patients with HCV. A large national study published in the journal Digestive Diseases in September 2025 identified delayed diagnosis in 90% of patients with chronic hepatitis C, and 75% of patients experienced liver complications, despite availability of DAA treatment. This study also found that the majority of hepatitis C patients started DAA treatment after a liver complication had occurred, and only 6% of nondelayed diagnosis patients started DAA treatment more than two years before liver complications occurred. For individuals with HCV infection, the AASLD/IDSA guidelines include simplified HCV treatment algorithms for adults who have never been treated without cirrhosis. These simplified algorithms decrease requirements for pretreatment assessments for uncomplicated patients and are intended to be used by any health care provider knowledgeable about HCV treatment as long as they can consult a specialist if needed. The AASLD-IDSA guidelines recommend DAA treatment for all adults with acute or chronic HCV infection (except for individuals with short life expectancy). There are currently five DAA treatments available. Typical treatment duration is 8 to 12 weeks; some patients with decompensated cirrhosis receive treatment for 24 weeks. Three DAAs are pangenotypic (the treatments specified in this bill, applicable to any HCV genotype) and considered first-line treatment.
Although the guidelines continue to recommend interventions and lifestyle changes to prevent further liver damage, they no longer condition initiation of antiviral therapy on abstinence from alcohol or sobriety testing, genotype testing, or other tests for cirrhosis. According to CHBRP, as guidelines have continued to evolve, prior authorization requirements have not kept pace with updated guidelines by continuing to require pretreatment assessments. Pretreatment assessments commonly required as part of prior authorization requirements include those prohibited under this bill.
- Prior authorization. Prior authorization is a form of utilization review or utilization management. California has a standardized form for prior authorization submissions. If a health plan or insurer fails to respond to the prior authorization request within 72 hours for nonurgent requests, and within 24 hours if exigent circumstances exist, upon the receipt of a completed form, the request is deemed granted. In 2023, at the request of the Legislature, CHBRP conducted a survey of California-regulated plans and insurers and found that overall, between 5% and 15% of all covered medical services, and between 16% and 25% of pharmacy benefits, were subject to prior authorization requirements. While there were significant differences among plans, some of the most frequently requested services and treatments were not necessarily the most expensive categories of treatments. Many under the medical benefit were services or treatment for ongoing care, such as behavioral health services and physical, occupational, or speech therapies. Some were rare or more expensive, but with low utilization rates.
- SB 306 process. A growing number of bills have been introduced over the past ten years to remove health plan and insurer prior authorization requirements for a variety of health care services and treatments. Last year the Legislature passed, and the Governor signed, SB 306 (Becker, Chapter 408, Statutes of 2025), which will exempt health care services that have high approval rates (90% or higher) from prior authorization by health plans and insurers. During the debate over SB 306, supporters stated that insurance companies frequently use prior authorization as a cost-control tool, but that it often results in delays or denials of essential treatments for patients. SB 306 set up a process by which high-approval services do not require prior authorization. In July 2026, plans and insurers began reporting information to their regulators about prior authorization approval rates, and regulators are required to publish a list of services that receive prior authorization at least 90% of the time. Beginning January 1, 2028, health plans and insurers will cease requiring prior authorizations for services with high approval rates as identified by the regulators. DMHC/CDI are also required to publish a report regarding the impact of the cessation of prior authorization requirements and include data on the volume of covered health care services subjected to prior authorization, statistics on prior authorization requests and determinations, administrative costs, timely access to care, enrollee health outcomes, and data on reinstatements of prior authorization.
SB 306 allows health plans and insurers to continue prior authorizations on a variety of services, such as a novel application of existing therapy, services by an out-of-network or noncontracting provider, clear and convincing concerns about fraud or clinically inappropriate care, and services that are used differently from the use approved or cleared by the FDA. Additionally, outpatient drugs in Tier 3 or Tier 4 of a drug formulary are excluded from the SB 306 process. Tier 3 and Tier 4 drugs are defined in existing law as brand name drugs that generally have a preferred and less costly therapeutic alternative at a lower tier and specialty drugs. The drugs specified under this bill are Tier 3 and 4 drugs.
- CHBRP report. AB 1996 (Thomson, Chapter 795, Statutes of 2002) requests the University of California to assess legislation proposing a mandated benefit or service and prepare a written analysis with relevant data on the medical, economic, and public health impacts of proposed health plan and health insurance benefit mandate legislation. CHBRP was created in response to AB 1996 and reviewed this bill. Key findings include:
- Benefit Coverage. Among the 13.2 million enrollees with a state-regulated pharmacy benefit, CHBRP estimates 5.7 million enrollees (43%) are in plans or policies out of compliance with this bill due to prior authorization requirements, and 7.5 million enrollees (57%) are in plans or policies that are compliant. This bill would not exceed essential health benefits.
- Medical Effectiveness. There is very strong evidence that DAAs are effective at treating hepatitis C, with cure rates above 95% for most medications. There is strong evidence that there is no difference in effectiveness among DAAs. There is some evidence that removing prior authorization requirements leads to increased utilization of DAAs and not enough research to determine whether removing prior authorization for DAAs improves health outcomes.
- Cost Impacts. Among the 3,423 enrollees with a state-regulated pharmacy benefit that included prior authorization requirements at baseline who are diagnosed with hepatitis C within the first year, approximately 10% (or 342 enrollees) would receive DAAs. Postmandate, these enrollees would avoid an estimated 924 pretreatment tests and services per year from the removal of prior authorization requirements, resulting in an annual estimated decrease of $346 in costs per enrollee. Furthermore, postmandate, CHBRP estimates the treatment rate for enrollees diagnosed with hepatitis C would increase to 11%, leading to 34 additional enrollees receiving DAAs to treat hepatitis C at a cost of $33,000 per course of treatment. Of these newly treated enrollees, 95% are estimated to be cured, reducing average annual costs associated with clinical complications of untreated hepatitis C by $7,650 per enrollee, resulting in the change in their expenses to range from a decrease of $895 to an increase of $644 depending on the market segment and plan design. Total annual premiums would increase by $708,000, paid by employers and enrollees ($0.0020-$0.0134 per member per month). This premium increase applies to all enrollees regardless of whether they use the benefit. Aggregate cost sharing among enrollees who use DAAs would decrease by $40,000.
- Public Health Impacts. CHBRP projects no measurable public health impact at the population level due to the small, estimated increase in utilization. However, this bill would likely yield health and quality-of-life improvements for the 34 additional enrollees using DAAs and the 342 enrollees avoiding pretreatment assessments no longer required under prior authorization. Barriers related to cost sharing and access to screening and treatment may remain.
- Long-Term Impacts. Recent updates to HCV treatment guidelines have expanded eligibility, decreased requirements for testing and monitoring, and emphasized that HCV treatment can often be managed by nonspecialist providers. Increased uptake of the recently updated guidelines in conjunction with the removal of prior authorization is likely to increase the number of nonspecialists prescribing DAA therapy for patients with HCV infection, thereby increasing access to treatment and cure.
- Related legislation. AB 1887 (Zbur) would prohibit prior authorization, step therapy, or any other utilization management for a drug approved for the treatment of a rare disease, as specified. AB 1887 is set for hearing on July 1, 2026 in this Committee.
- Prior legislation. SB 306 (Becker, Chapter 408, Statutes of 2025) excludes, from health plan and insurer prior authorization requirements, health care services that have been approved by the plan or insurer 90% or more of the time, as determined by DMHC/CDI after evaluation of health plan and insurer reporting. SB 306 sunsets on January 1, 2034.
AB 554 (Gonzalez and Haney of 2025) would have prohibited nongrandfathered health plans (established by the federal Affordable Care Act) and insurance policies from imposing any cost-sharing for antiretroviral drugs, devices, or drug products that are approved by the FDA for PreP. AB 554 would have applied its provisions and the law it amends to an antiretroviral drug, drug device, or drug product regardless of whether or not it is self-administered. AB 554 was vetoed by Governor Newsom, who stated, in part: “…certain components of this measure raise concerns about affordability. By exceeding the cost-sharing provisions under the ACA, this bill would result in increased costs to health plans, which would then be passed on to consumers. At a time when individuals are facing double-digit rate increases in their health care premiums across the nation, the state must weigh the potential benefits of all new mandates against the comprehensive costs to the entire health care delivery system.”
SB 339 (Weiner, Chapter 1, Statutes of 2024) permits a pharmacist to furnish up to a 90-day course of PrEP, or beyond 90-days if specified conditions are met. Requires a health plan/insurer to cover PrEP and PEP furnished by a pharmacist, including costs for the pharmacist’s services and related testing ordered by the pharmacist.
SB 159 (Weiner, Chapter 532, Statutes of 2019) prohibits health plans/insurers from requiring prior authorization or step therapy for PrEP or PEP, and requires coverage of pharmacist-prescribed PrEP and PEP. Prohibits health plans/insurers from covering PrEP furnished by a pharmacist in excess of a 60-day supply to a single patient once every two years, unless the pharmacist has been directed otherwise by a prescriber. Allows Medi-Cal reimbursement for pharmacists prescribing PrEP and PEP.
- Support. San Francisco AIDS Foundation and End Hep C SF write that the definitive
medical guidelines for hepatitis C treatment in the U.S., published by AASLD-IDSA, recommend timely treatment for almost all people living with HCV. The guidelines also note that treating hepatitis C is highly cost-effective. Treating hepatitis C saves the health care system money. This stands to reason: the cost of a single course of medication is much lower than the cost of treating a lifetime of complications like cirrhosis and liver failure (and the cost of treating one person with HCV is clearly lower than the cost of treating multiple people to whom the first person may otherwise transmit the virus). Supporters state that based on the AASLD-IDSA guidelines and cost-effectiveness analyses, the Department of Health Care Services has in recent years eliminated from the Medi-Cal Rx formulary all potential barriers to treatment, including prior-authorization requirements. In contrast, many commercial health insurers selling policies in California do impose prior authorization requirements on treatment. In addition, as part of their processes, many of these insurers request information or procedures that are no longer required for treatment. For example, some insurers ask for the “genotype” (i.e., distinct genetic strain) of the patient’s HCV, but current medications treat all genotypes (i.e., are “pangenotypic”). Others request liver biopsies, which are not recommended before HCV treatment–but are costly and dangerous. Requiring prior authorization for HCV medications and requesting unnecessary information or procedures as part of their processes, often results in people with HCV not getting the treatment they need. Both surveys of providers and analyses of patient data indicate that prior authorization causes delays in care, treatment abandonment, and ultimately worse health. Many people with HCV have a history of injection drug use and/or incarceration, so may face a high level of instability in their lives. This puts them at elevated risk of falling out of care due to barriers such as prior authorization. About two thirds of people who have private insurance and are diagnosed with HCV do not successfully initiate treatment within 360 days; prior authorization is one reason why.
- Opposition. The Association of California Life & Health Insurance Companies and California Association of Health Plans (ACLHIC/CAHP) writes that while they appreciate the intent of this bill, they oppose the provisions of the bill that would limit a health plan’s/insurer’s ability to conduct prior authorization. Just last year, the Legislature enacted SB 306, establishing a comprehensive regulatory process to evaluate the use of prior authorization and determine which services and medications should be exempt from those requirements. As part of that process, the Legislature specifically considered whether specialty drugs, particularly higher-cost Tier 3 and Tier 4 medications, should be exempt. Ultimately, they determined these medications should remain subject to prior authorization requirements. That decision reflected the significant costs associated with many of these medications and the important role prior authorization can play in helping ensure enrollees receive clinically appropriate treatment at the lowest available cost. By removing prior authorization requirements for certain drugs used to treat hepatitis C, this bill would deviate from the Legislature’s recent and deliberate policy decision to maintain utilization management safeguards for higher-cost specialty medications. Additionally, ACLHIC/CAHP remain concerned with the provision of the bill that would codify specific clinical criteria and treatment guidelines into statute. While clinical guidelines can help inform evidence-based care and establish the efficacy and safety of diagnostic tests or therapeutic interventions, codifying them into law is problematic because medical evidence and standards of care evolve over time. Guidelines are intended to support, not replace, individualized clinical decision-making, and patient needs may vary significantly from the populations on which the guidelines are based. As a result, statutory clinical requirements risk becoming outdated and may reduce the flexibility needed to incorporate new evidence and advances in care.
SUPPORT AND OPPOSITION:
Support: End Hep C San Francisco (co-sponsor)
San Francisco AIDS Foundation (co-sponsor)
Access Support Network
AIDS Healthcare Foundation
APLA Health
Beyond AIDS Foundation
Bienestar Human Services
California Academy of Preventive Medicine
California & Hawai’i Chapter of the American Academy of HIV Medicine
California LGBTQ Health and Human Services Network
California Life Sciences Association
California Medical Association
Community Health Project Los Angeles
County Health Executives Association of California
DAP Health
Drug Policy Alliance
GLIDE
Health Access California
Health Officers Association of California
HealthRIGHT 360
Insurance Commissioner Ricardo Lara / California Department of Insurance
Kedren Community Health Center
Liver Coalition of San Diego
National Health Law Program
Sunburst Projects
Oppose: Association of California Life & Health Insurance Companies
California Association of Health Plans
-- END --
ASSEMBLY THIRD READING
ATR Bill Id:AB 1843
Author:(Elhawary)
As Amended Ver:March 2, 2026
Majority vote
SUMMARY
Prohibits a health plan or health insurer from subjecting direct-acting antiviral drugs that are medically necessary for the treatment of hepatitis C to prior authorization (PA), as specified.
Major Provisions
COMMENTS
Hepatitis C is a liver disease caused by infection from the hepatitis C virus (HCV), which is transmitted through exposure to infected blood or bodily fluids containing infected blood. Acute hepatitis C occurs within the first 6 months of exposure to HCV; chronic hepatitis C occurs if acute hepatitis C is not recognized and treated and the virus is not cleared by the body within 6 months. Studies estimate that acute hepatitis C leads to chronic infection in most patients. HCV is primarily transmitted by sharing contaminated needles, syringes, or other equipment used to prepare or inject drugs; other risk factors for transmission include multiple sexual partners, nonprofessional tattoo or piercing, prior incarceration, workplace exposure to needle sticks, or being born to an HCV-infected person. Individuals with hepatitis C can develop cirrhosis (advanced, irreversible scarring of the liver that leads to liver failure), liver cancer, and other liver- and non-liver–related complications and are at increased risk of premature death. Based on Department of Public Health data from 2018 (the most recent statewide surveillance data available), the annual rate of newly reported cases of chronic hepatitis C is estimated at 89 cases per 100,000 population in California (about 35,500 cases), which is a 10% decrease from 2017.
California Health Benefits Review Program (CHBRP). CHBRP was created in response to AB 1996 (Thomson), Chapter 795, Statutes of 2002, which requests the University of California to assess legislation proposing a mandated benefit or service and prepare a written analysis with relevant data on the medical, economic, and public health impacts of proposed health plan and health insurance benefit mandate legislation. SB 125 (Hernandez), Chapter 9, Statutes of 2015, added an impact assessment on essential health benefits (EHBs), and legislation that impacts health insurance benefit designs, cost-sharing, premiums, and other health insurance topics to CHBRP's purview. CHBRP reviewed this bill and included the following impact estimates in their analysis:
- Premium increases & enrollee out-of-pocket decreases. Premiums paid by employers and enrollees would increase upon enaction of this bill by an estimated $708,000 ($0.0020-$0.0134 per member per month). This premium increase applies to all enrollees regardless of whether they use the benefit. Aggregate cost sharing among enrollees who use direct-acting antiviral drugs would decrease by $40,000.
- Increased utilization of care. CHBRP estimates the treatment rate for enrollees diagnosed with hepatitis C would increase to 11%, leading to 34 additional enrollees receiving direct-acting antiviral drugs to treat hepatitis C. Of these newly treated enrollees, 95% are estimated to be cured, reducing average annual costs associated with clinical complications of untreated hepatitis C by $7,650 per enrollee.
- Medical effectiveness. CHBRP determined there is very strong evidence that direct-acting antiviral drugs are effective at treating hepatitis C, with cure rates above 95% for most medications. There is strong evidence that there is no difference in effectiveness among different direct-acting antiviral drugs. There is some evidence that removing prior authorization PA requirements leads to increased utilization of direct-acting antiviral drugs and not enough research to determine whether removing PA for direct-acting antiviral drugs improves health outcomes.
- Public health impacts. CHRBP determined that this bill would produce no measurable short-term public health impact at the population level due to the small estimated increase in utilization. However, this bill would likely yield health and quality-of-life improvements for the 34 additional enrollees using direct-acting antiviral drugs and the 342 enrollees avoiding pretreatment assessments no longer required under PA. Barriers related to cost sharing and access to screening and treatment may remain.
Utilization Management (UM) and Utilization Review (UR). UM and UR are processes used by health plans to evaluate and manage the use of health care services. UR can occur prospectively, retrospectively, or concurrently and a plan can approve, modify, delay or deny in whole or in part a request based on its medical necessity. PA is a UR technique used by health plans that requires patients to obtain approval of a service or medication before care is provided. PA is intended to allow plans to evaluate whether care that has been prescribed is medically necessary for purposes of coverage. PA is one type of UM tool that's used by health plans, along with others such as concurrent review and step therapy, to control costs, limit unnecessary care, and evaluate safety and appropriateness of a service.
Overall impact of PA. In 2023, CHBRP published a report to help the Legislature better understand the ways in which PA is used in California. CHBRP noted that PA is an imperfect instrument that is utilized in a myriad of ways. This poses a challenge for policymakers, payers, patients, and providers since PA is generally intended to decrease costs, but it may also contribute to delays in treatment and additional barriers to care. Currently, evidence is limited as to the extent to which health insurance uses PA and its impact on the performance of the health care system, patient access to appropriate care, and the health and financial interests of the general public. Despite the limited evidence, there is clear frustration from both patients and providers regarding PA practices. According to CHBRP, complaints range from the time required to complete the initial authorization request and pursue denials, to delays in care, to a general lack of transparency regarding the process and criteria used to evaluate PA requests. CHBRP further notes that people with disabilities, younger patients, African Americans, and people with lower incomes are more likely to report administrative burdens, including delays in care, due to PA.
Office of Health Care Affordability (OHCA) cost targets. OHCA was established in 2022 in response to widespread cost-related access challenges across California. According to the California Health Care Foundation (CHCF), over half of Californians say they skip or delay health care due to costs. OHCA collects, analyzes, and publicly reports data on total health care expenditures and enforces spending targets. OHCA's spending targets are intended to reduce excess spending and slow health care spending growth. In April of 2024, OHCA approved a statewide cost growth target of 3.5% starting in 2025 and phasing down to 3% by 2029. Health care entities, including health plans and insurers, are subject to the statewide spending target and are subject to progressive enforcement if the entity's costs exceed the target. Some entities have raised concerns that new legislative insurance mandates will make it difficult for them to meet the established cost growth target.
Current law does not explicitly require OHCA to adjust the cost growth targets based on changes to state policy, such as insurance mandates, that may increase spending. However, it does require OHCA to consider state benefit mandates in its development and enforcement of cost growth targets. Specifically, when establishing cost growth target methodology, OHCA is required to review relevant state policy changes impacting covered benefits, provider reimbursement, and costs, among other factors. In addition, in enforcing cost growth targets, OHCA is required to consider factors that contribute to spending in excess of the applicable target, and the extent to which each entity has control over the applicable components of its cost target.
According to the Author
Hepatitis C is a life-threatening disease that disproportionately affects marginalized communities if left untreated, but it is highly curable, with modern treatments curing over 95% of infections. The author continues that this bill ensures health plans follow current medical guidelines and eliminate extra requirements that are not medically necessary for accessing treatment. The author concludes that by streamlining access to care, this bill helps prevent serious health complications, reduces transmission, saves lives, reduces long-term healthcare costs, and moves California closer to eliminating hepatitis C.
Arguments in Support
End Hep C SF supports this bill, stating that reducing barriers to HCV treatment access is essential to achieving elimination and ensuring people can access timely, and life-saving care. End Hep C SF notes that based on the clinical guidelines in this bill and cost-effectiveness analyses, the Department of Health Care Services has in recent years eliminated from the Medi-Cal Rx formulary all potential barriers to treatment, including PA requirements. In contrast, End Hep C SF states that many commercial health insurers selling policies in California do impose PA requirements on treatment. In addition, as part of their PA processes, many of these insurers request information or procedures that are no longer required for treatment. End Hep C SF shares the example that some insurers ask for the "genotype" (i.e., distinct genetic strain) of the patient's HCV, but current medications treat all genotypes. End Hep C SF continues that others request liver biopsies, which are not recommended before HCV treatment–but are costly and dangerous. End Hep C SF argues that requiring PA for HCV medications and requesting unnecessary information or procedures as part of PA processes, often results in people with HCV not getting the treatment they need. End Hep C SF continues that the Legislature and Governor Newsom enacted SB 306 (Becker), Chapter 408, Statutes of 2025, in an effort to comprehensively reform PA. Unfortunately, End Hep C SF notes that bill does not apply to drugs in tier three or four of a health insurer's formulary, and current first-line treatments for HCV are all typically placed in those tiers. End Hep C SF argues that to solve the problem of PA for hepatitis C treatment, the Legislature must go one step further. End Hep C SF concludes that removing unneeded impediments to HCV treatment for Californians with commercial insurance—just as the state has done for Medi-Cal enrollees—will clear the way for people with HCV to get cured, lowering health care spending and bringing us closer to ending the HCV epidemic in the Golden State.
Arguments in Opposition
The California Association of Health Plans and Association of California Life Insurance Companies are opposed to this bill, stating that this bill can impact a plan's ability to manage healthcare spending at a time when healthcare spending is at an all time high. Additionally, the opposition notes that they are also concerned with the provision of the bill that requires health plans/insurers to align their clinical criteria with the standards set by the American Association for the Study of Liver Diseases and the Infectious Diseases Society of America. The opposition notes that while guidelines can help establish the efficacy and safety of diagnostic testing or therapeutic interventions, codifying them into law is problematic because populations might differ and treatment evidence may evolve. Finally, the opposition continues to remain opposed to the high cost of prescription drugs, noting that cost of the drugs under this bill – which are a one time treatment – can be as high as $33,000. The opposition urges the Legislature, as they consider mandates that affect a health plan's/insurer's ability to manage costs, to take careful consideration of the significant costs associated with prescription drugs, which continue to be one of the primary drivers of health care spending.
FISCAL COMMENTS
According to the Assembly Committee on Appropriations:
- Costs to the Department Insurance (CDI) of $7,000 in fiscal year (FY) 2026-27 and $19,000 in FY 2027-28 to review forms for compliance (Insurance Fund).
- The Department of Managed Health Care (DMHC) anticipates minor and absorbable costs.
- CHBRP estimates this bill would increase premiums for DMHC-regulated plans in the California Public Employees Retirement System (CalPERS) by $38,000, of which about $18,000 would be state General Fund costs. There would be additional General Fund costs for the CDI-regulated CalPERS insurance policies, possibly around $10,000.
- No costs to the Medi-Cal program.
VOTES
ASM HEALTH: 12-2-2
YES: Bonta, Addis, Aguiar-Curry, Ahrens, Caloza, Carrillo, Mark González, Patel, Rogers, Schiavo, Sharp-Collins, Stefani
NO: Johnson, Sanchez
ABS, ABST OR NV: Chen, Patterson
ASM APPROPRIATIONS: 10-2-3
YES: Wicks, Aguiar-Curry, Caloza, Fong, Mark González, Krell, Pacheco, Pellerin, Sharp-Collins, Solache
NO: Hoover, Tangipa
ABS, ABST OR NV: Arambula, Dixon, Ta
UPDATED
VERSION: March 2, 2026
CONSULTANT: Riana King / HEALTH / (916) 319-2097 FN: 0002482
Date of Hearing: May 6, 2026
ASSEMBLY COMMITTEE ON APPROPRIATIONS
Buffy Wicks, Chair
ABPCA Bill Id:AB 1843
Author:(Elhawary) – As Amended Ver:March 2, 2026
Policy Committee: | Health | Vote: | 12 - 2 |
|
| ||
|
|
Urgency: No State Mandated Local Program: Yes Reimbursable: No
SUMMARY:
This bill prohibits a health care service plan and health insurer (collectively, health plan) from subjecting medically necessary direct-acting antiviral drugs for the treatment of hepatitis C to prior authorization (PA).
Specifically, this bill:
- Prohibits a health plan from subjecting direct-acting antiviral drugs that are medically necessary for the treatment of hepatitis C, including, but not limited to, sofosbuvir/velpatasvir, sofosbuvir/ledipasvir, glecaprevir/pibrentasvir, or elbasvir/grazoprevir, to PA, except as provided in item 2, below.
- Allows a health plan to not cover every therapeutically equivalent version of a drug, device, or product for the treatment of hepatitis C, without PA, if the U.S. Food and Drug Administration (FDA) has approved one or more therapeutic equivalents and at least one therapeutically equivalent version is covered without PA.
- Requires a health plan’s clinical criteria for hepatitis C treatment and PA to align with current guidelines and the standard of care, as specified and prohibits PA requirements, including the following:
- A liver biopsy.
- Genotype testing.
- Sobriety requirements.
- Fibrosis staging thresholds.
- Elastography or FibroScan documentation.
- Ultrasound documentation.
- A specialist referral or evaluation.
FISCAL EFFECT:
Costs to the Department Insurance of $7,000 in fiscal year (FY) 2026-27 and $19,000 in FY 2027-28 to review forms for compliance (Insurance Fund).
The Department of Managed Health Care (DMHC) anticipates minor and absorbable costs.
The California Health Benefits Review Program (CHBRP) estimates this bill would increase premiums for DMHC-regulated plans in the California Public Employees Retirement System (CalPERS) by $38,000, of which about $18,000 would be state General Fund costs. There would be additional General Fund costs for the CDI-regulated CalPERS insurance policies, possibly around $10,000.
No costs to the Medi-Cal program.
COMMENTS:
- Purpose. This bill is sponsored by San Francisco Aids Foundation and End HepC SF. According to the author:
Hepatitis C is a life-threatening disease that disproportionately affects marginalized communities if left untreated, but it is highly curable, with modern treatments curing over 95% of infections.
This bill ensures health plans follow current medical guidelines and eliminate extra requirements that are not medically necessary for accessing treatment. By streamlining access to care, [This bill] helps prevent serious health complications, reduces transmission, saves lives, reduces long-term healthcare costs, and moves California closer to eliminating hepatitis C.
- Background. Hepatitis C is a liver disease caused by infection from the hepatitis C virus (HCV), which is transmitted through exposure to infected blood. Acute hepatitis C occurs within the first 6 months of exposure to HCV; chronic hepatitis C occurs if acute hepatitis C is not recognized and treated and the virus is not cleared by the body within 6 months. Acute hepatitis C leads to chronic infection in most patients. Most people with acute and chronic Hepatitis C are asymptomatic, and evidence suggests one-third of people with hepatitis C are unaware they are infected and can transmit the virus to others. Studies estimate that, on average, one person with HCV infection transmits it to one to four others. HCV is primarily transmitted by sharing contaminated needles, syringes, or other equipment used to prepare or inject drugs. Other risk factors for HCV infection include multiple sexual partners, nonprofessional tattoo or piercing, prior incarceration, workplace exposure to needle sticks, or being born to an HCV-infected person.
CHBRP states the average cost for a course of DAA treatment is $33,000, including an average enrollee cost share of $1,094. CHBRP estimates that this bill would increase the treatment rate for enrollees diagnosed with hepatitis C to 11%, leading to 34 additional enrollees receiving direct-acting antiviral drugs for treatment. CHBRP projects that of these newly treated enrollees, 95% will be cured, reducing average annual costs associated with clinical complications of untreated hepatitis C by $7,650 per treated enrollee.
- Opposition. The California Association of Health Plans and Association of California Life Insurance Companies state this bill could impact a plan’s ability to manage healthcare spending, among other arguments. The opposition urges the Legislature, as they consider mandates that affect a health plan’s/insurer’s ability to manage costs, to take careful consideration of the significant costs associated with prescription drugs, which continue to be one of the primary drivers of health care spending.
- Related Legislation. SB 306 (Becker), Chapter 408, Statutes of 2025, excludes from PA requirements covered health care services that have been approved by the plan or insurer 90% or more of the time.
Analysis Prepared by: Allegra Kim / APPR. / (916) 319-2081
Date of Hearing: April 21, 2026
ASSEMBLY COMMITTEE ON HEALTH
Mia Bonta, Chair
ABPCA Bill Id:AB 1843
Author:(Elhawary) – As Amended Ver:March 2, 2026
SUBJECT: Communicable diseases: hepatitis B and C.
SUMMARY: Prohibits a health plan or health insurer from subjecting direct-acting antiviral drugs that are medically necessary for the treatment of hepatitis C to prior authorization (PA), as specified. Specifically, this bill:
- Prohibits a health plan or health insurer from subjecting direct-acting antiviral drugs that are medically necessary for the treatment of hepatitis C, including, but not limited to, sofosbuvir/velpatasvir, sofosbuvir/ledipasvir, glecaprevir/pibrentasvir, or elbasvir/grazoprevir, to PA, except for as provided in 2) below.
- Permits, if the United States Food and Drug Administration (FDA) has approved one or more therapeutic equivalents of a drug, device, or product for the treatment of hepatitis C, a health plan or insurer to not cover all of the therapeutically equivalent versions without PA, if at least one therapeutically equivalent version is covered without prior PA.
- Requires a health plan or insurers clinical criteria for hepatitis C treatment and PA to align with current guidelines and the standard of care consistent with the standards of the American Association for the Study of Liver Diseases and the Infectious Diseases Society of America. Prohibits PA requirements, including, but not limited to, all of the following:
- A liver biopsy;
- Genotype testing;
- Sobriety requirements;
- Fibrosis staging thresholds;
- Elastography or FibroScan documentation;
- Ultrasound documentation; and,
- A specialist referral or evaluation.
EXISTING LAW:
- Establishes the Department of Managed Health Care (DMHC) to regulate health plans under the Knox-Keene Health Care Service Plan Act of 1975 (Knox-Keene Act) and California Department of Insurance (CDI) to regulate health and other insurance. [Health & Safety Code (HSC) § 1340, et seq. and Insurance Code (INS) § 106, et seq.]
- Establishes California's essential health benefits (EHBs) benchmark under the Patient Protection and Affordable Care Act (ACA) as the Kaiser Small Group Health Maintenance Organization, establishes existing California health insurance mandates, and the 10 ACA mandated benefits, including prescription drug coverage. [HSC § 1367.005 and INS § 10112.27]
- Defines “basic health care services” as all of the following:
- Physician services, including consultation and referral;
- Hospital inpatient services and ambulatory care services;
- Diagnostic laboratory and therapeutic radiologic services;
- Home health services;
- Preventive health services;
- Emergency health care services, including ambulance and ambulance transport services and out-of-area coverage. Basic health care services includes ambulance and ambulance transport services provided through the 911 emergency response system; and,
- Hospice care, as specified. [HSC § 1345 and INS § 10112.281]
- Requires the criteria or guidelines used by health plans and insurers, or any entities with which plans or insurers contract for utilization review (UR) or utilization management (UM) functions, to determine whether to authorize, modify, or deny health care services to:
- Be developed with involvement from actively practicing health care providers;
- Be consistent with sound clinical principles and processes;
- Be evaluated, and updated if necessary, at least annually;
- If used as the basis of a decision to modify, delay, or deny services in a specified case under review, be disclosed to the provider and the enrollee or insured in that specified case; and,
- Be available to the public upon request. [HSC § 1363.5 and INS § 10123.135]
- Requires health plans and disability insurers and any contracted entity that performs UR or UM functions, prospectively, retrospectively, or concurrently, based on medical necessity requests to comply with specified requirements. [HSC § 1367.01 and INS § 10123.135]
- Requires decisions to approve, modify, or deny, based on medical necessity, requests by providers prior to, or concurrent with the provision of health care services to be made in a timely fashion that does not to exceed five business days from the health plan or health insurer’s receipt of the information reasonably necessary and requested by the plan to make the determination. Requires, in cases where the review is retrospective, the decision to be communicated to the individual who received services, or to the individual’s designee, within 30 days of the receipt of information that is reasonably necessary to make this determination, and be communicated to the provider in a manner that is consistent with current law. [HSC § 1367.01 and INS § 10123.135]
- Requires decisions to approve, modify, or deny requests by providers prior to, or concurrent with, the provision of health care services, to be made in a timely fashion appropriate for the nature of the enrollee or insured’s condition, not to exceed 72 hours when an individual’s condition is such that they face an imminent and serious threat to their health, including, but not limited to, the potential loss of life, limb, or other major bodily function, or the normal timeframe for the decision-making process would be detrimental to the enrollee’s life or health or could jeopardize the enrollee’s ability to regain maximum function, after the plan’s receipt of the information reasonably necessary and requested by the plan to make the determination. [HSC § 1367.01 and INS § 10123.135]
- Authorizes a health care provider or prescribing provider, enrollee, insured, or their designee or guardian to appeal a denial of an exception request for coverage of a nonformulary drug, prior authorization request, or step therapy exception request consistent with the plan’s or insurer’s current UM process. [HSC § 1367.206 and INS § 10123.201]
- Prohibits a health plan or insurer from subjecting antiretroviral drugs that are medically necessary for the prevention of AIDS/HIV, including PrEP or PEP, to PA or step therapy. Permits a health plan or insurer not to cover all of the therapeutically equivalent versions without PA or step therapy, if at least one therapeutically equivalent version is covered without PA or step therapy, if the FDA has approved one or more therapeutic equivalents of a drug, device, or product for the prevention of AIDS/HIV. Limits coverage to a 60-day supply to a single patient once every two years, unless the pharmacist has been directed otherwise by a prescriber. [HSC § 1342.74 and INS § 10123.1933]
- Excludes from health plan and insurer PA requirements specified covered health care service that have been approved by the plan or insurer 90% or more times as determined by DMHC and CDI after health plan and insurer reporting and evaluation by DMHC and CDI. [HSC § 1367.025 and INS § 10133.52]
- Establishes the California Health Care Quality and Affordability Act, which creates the Office of Health Care Affordability (OHCA) within the Department of Health Care Access and Information (HCAI). Identifies OHCA’s three primary responsibilities: managing spending targets, monitoring system performance, and assessing market consolidation. Requires OHCA to collect, analyze, and publicly report data on total health care expenditures, and enforce spending targets set by a Health Care Affordability Board (Board). [HSC § 127500, et seq.]
FISCAL EFFECT: Unknown. This bill has not been analyzed by a fiscal committee.
COMMENTS:
- PURPOSE OF THIS BILL. According to the author, hepatitis C is a life-threatening disease that disproportionately affects marginalized communities if left untreated, but it is highly curable, with modern treatments curing over 95% of infections. The author continues that this bill ensures health plans follow current medical guidelines and eliminate extra requirements that are not medically necessary for accessing treatment. The author concludes that by streamlining access to care, this bill helps prevent serious health complications, reduces transmission, saves lives, reduces long-term healthcare costs, and moves California closer to eliminating hepatitis C.
- BACKGROUND. Hepatitis C is a liver disease caused by infection from the hepatitis C virus (HCV), which is transmitted through exposure to infected blood or bodily fluids containing infected blood. Acute hepatitis C occurs within the first 6 months of exposure to HCV; chronic hepatitis C occurs if acute hepatitis C is not recognized and treated and the virus is not cleared by the body within 6 months. Studies estimate that acute hepatitis C leads to chronic infection in most patients. HCV is primarily transmitted by sharing contaminated needles, syringes, or other equipment used to prepare or inject drugs; other risk factors for transmission include multiple sexual partners, nonprofessional tattoo or piercing, prior incarceration, workplace exposure to needle sticks, or being born to an HCV-infected person. Individuals with hepatitis C can develop cirrhosis (advanced, irreversible scarring of the liver that leads to liver failure), liver cancer, and other liver- and non-liver–related complications and are at increased risk of premature death. Based on Department of Public Health data from 2018 (the most recent statewide surveillance data available), the annual rate of newly reported cases of chronic hepatitis C is estimated at 89 cases per 100,000 population in California (about 35,500 cases), which is a 10% decrease from 2017.
- California Health Benefits Review Program (CHBRP). CHBRP was created in response to AB 1996 (Thomson), Chapter 795, Statutes of 2002, which requests the University of California to assess legislation proposing a mandated benefit or service and prepare a written analysis with relevant data on the medical, economic, and public health impacts of proposed health plan and health insurance benefit mandate legislation. SB 125 (Hernandez), Chapter 9, Statutes of 2015, added an impact assessment on EHBs, and legislation that impacts health insurance benefit designs, cost-sharing, premiums, and other health insurance topics to CHBRP’s purview. CHBRP reviewed this bill and included the following impact estimates in their analysis:
- Premium increases & enrollee out-of-pocket decreases. Premiums paid by employers and enrollees would increase upon enaction of this bill by an estimated $708,000 ($0.0020-$0.0134 per member per month). This premium increase applies to all enrollees regardless of whether they use the benefit. Aggregate cost sharing among enrollees who use direct-acting antiviral drugs would decrease by $40,000.
- Increased utilization of care. CHBRP estimates the treatment rate for enrollees diagnosed with hepatitis C would increase to 11%, leading to 34 additional enrollees receiving direct-acting antiviral drugs to treat hepatitis C. Of these newly treated enrollees, 95% are estimated to be cured, reducing average annual costs associated with clinical complications of untreated hepatitis C by $7,650 per enrollee.
- Medical effectiveness. CHBRP determined there is very strong evidence that direct-acting antiviral drugs are effective at treating hepatitis C, with cure rates above 95% for most medications. There is strong evidence that there is no difference in effectiveness among different direct-acting antiviral drugs. There is some evidence that removing PA requirements leads to increased utilization of direct-acting antiviral drugs and not enough research to determine whether removing PA for direct-acting antiviral drugs improves health outcomes.
- Public health impacts. CHRBP determined that this bill would produce no measurable short-term public health impact at the population level due to the small estimated increase in utilization. However, this bill would likely yield health and quality-of-life improvements for the 34 additional enrollees using direct-acting antiviral drugs and the 342 enrollees avoiding pretreatment assessments no longer required under PA. Barriers related to cost sharing and access to screening and treatment may remain.
- UM and UR. UM and UR are processes used by health plans to evaluate and manage the use of health care services. UR can occur prospectively, retrospectively, or concurrently and a plan can approve, modify, delay or deny in whole or in part a request based on its medical necessity. PA is a UR technique used by health plans that requires patients to obtain approval of a service or medication before care is provided. PA is intended to allow plans to evaluate whether care that has been prescribed is medically necessary for purposes of coverage. PA is one type of UM tool that’s used by health plans, along with others such as concurrent review and step therapy, to control costs, limit unnecessary care, and evaluate safety and appropriateness of a service.
- Overall impact of PA. In 2023, CHBRP published a report to help the Legislature better understand the ways in which PA is used in California. CHBRP noted that PA is an imperfect instrument that is utilized in a myriad of ways. This poses a challenge for policymakers, payers, patients, and providers since PA is generally intended to decrease costs, but it may also contribute to delays in treatment and additional barriers to care. Currently, evidence is limited as to the extent to which health insurance uses PA and its impact on the performance of the health care system, patient access to appropriate care, and the health and financial interests of the general public. Despite the limited evidence, there is clear frustration from both patients and providers regarding PA practices. According to CHBRP, complaints range from the time required to complete the initial authorization request and pursue denials, to delays in care, to a general lack of transparency regarding the process and criteria used to evaluate PA requests. CHBRP further notes that people with disabilities, younger patients, African Americans, and people with lower incomes are more likely to report administrative burdens, including delays in care, due to PA.
- OHCA cost targets. OHCA was established in 2022 in response to widespread cost-related access challenges across California. According to the California Health Care Foundation (CHCF), over half of Californians say they skip or delay health care due to costs. OHCA collects, analyzes, and publicly reports data on total health care expenditures and enforces spending targets. OHCA’s spending targets are intended to reduce excess spending and slow health care spending growth. In April of 2024, OHCA approved a statewide cost growth target of 3.5% starting in 2025 and phasing down to 3% by 2029. Health care entities, including health plans and insurers, are subject to the statewide spending target and are subject to progressive enforcement if the entity’s costs exceed the target. Some entities have raised concerns that new legislative insurance mandates will make it difficult for them to meet the established cost growth target.
- California Health Benefits Review Program (CHBRP). CHBRP was created in response to AB 1996 (Thomson), Chapter 795, Statutes of 2002, which requests the University of California to assess legislation proposing a mandated benefit or service and prepare a written analysis with relevant data on the medical, economic, and public health impacts of proposed health plan and health insurance benefit mandate legislation. SB 125 (Hernandez), Chapter 9, Statutes of 2015, added an impact assessment on EHBs, and legislation that impacts health insurance benefit designs, cost-sharing, premiums, and other health insurance topics to CHBRP’s purview. CHBRP reviewed this bill and included the following impact estimates in their analysis:
Current law does not explicitly require OHCA to adjust the cost growth targets based on changes to state policy, such as insurance mandates, that may increase spending. However, it does require OHCA to consider state benefit mandates in its development and enforcement of cost growth targets. Specifically, when establishing cost growth target methodology, OHCA is required to review relevant state policy changes impacting covered benefits, provider reimbursement, and costs, among other factors. In addition, in enforcing cost growth targets, OHCA is required to consider factors that contribute to spending in excess of the applicable target, and the extent to which each entity has control over the applicable components of its cost target.
- SUPPORT. End Hep C SF supports this bill, stating that reducing barriers to HCV treatment access is essential to achieving elimination and ensuring people can access timely, and life-saving care. End Hep C SF notes that based on the clinical guidelines in this bill and cost-effectiveness analyses, the Department of Health Care Services has in recent years eliminated from the Medi-Cal Rx formulary all potential barriers to treatment, including PA requirements. In contrast, End Hep C SF states that many commercial health insurers selling policies in California do impose PA requirements on treatment. In addition, as part of their PA processes, many of these insurers request information or procedures that are no longer required for treatment. End Hep C SF shares the example that some insurers ask for the “genotype” (i.e., distinct genetic strain) of the patient’s HCV, but current medications treat all genotypes. End Hep C SF continues that others request liver biopsies, which are not recommended before HCV treatment–but are costly and dangerous. End Hep C SF argues that requiring PA for HCV medications, and requesting unnecessary information or procedures as part of PA processes, often results in people with HCV not getting the treatment they need. End Hep C SF continues that the Legislature and Governor Newsom enacted Senate Bill 306 (Becker), Chapter 408, Statutes of 2025, in an effort to comprehensively reform PA. Unfortunately, End Hep C SF notes that bill does not apply to drugs in tier three or four of a health insurer’s formulary, and current first-line treatments for HCV are all typically placed in those tiers. End Hep C SF argues that to solve the problem of PA for hepatitis C treatment, the Legislature must go one step further. End Hep C SF concludes that removing unneeded impediments to HCV treatment for Californians with commercial insurance—just as the state has done for Medi-Cal enrollees—will clear the way for people with HCV to get cured, lowering health care spending and bringing us closer to ending the HCV epidemic in the Golden State.
- OPPOSITION. The California Association of Health Plans and Association of California Life Insurance Companies are opposed to this bill, stating that this bill can impact a plan’s ability to manage healthcare spending at a time when healthcare spending is at an all time high. Additionally, the opposition notes that they are also concerned with the provision of the bill that requires health plans/insurers to align their clinical criteria with the standards set by the American Association for the Study of Liver Diseases and the Infectious Diseases Society of America. The opposition notes that while guidelines can help establish the efficacy and safety of diagnostic testing or therapeutic interventions, codifying them into law is problematic because populations might differ and treatment evidence may evolve. Finally, the opposition continues to remain opposed to the high cost of prescription drugs, noting that cost of the drugs under this bill – which are a one time treatment – can be as high as $33,000. The opposition urges the Legislature, as they consider mandates that affect a health plan’s/insurer’s ability to manage costs, to take careful consideration of the significant costs associated with prescription drugs, which continue to be one of the primary drivers of health care spending.
- RELATED LEGISLATION. AB 1887 (Zbur) would prohibit PA, step therapy, or any other UM for a drug approved for the treatment of a rare disease, as specified. AB 1887 is currently pending in the Assembly Health Committee.
- PREVIOUS LEGISLATION.
- SB 306 (Becker) excludes from health plan and insurer prior authorization requirements specified covered health care service that have been approved by the plan or insurer 90% or more times as determined by DMHC and CDI after health plan and insurer reporting and evaluation by DMHC and CDI.
- AB 384 (Connolly) of 2025, would have prohibited a health plan, health insurer, or Medi-Cal from requiring PA for an individual to be admitted to medically necessary 24-hour inpatient settings for mental health and substance use disorders (SUDs) and for any medically necessary health care services provided to an individual while admitted for that care. AB 384 was held on the Assembly Appropriations Committee suspense file.
- AB 510 (Addis) of 2025, would have required, upon request, an appeal or grievance regarding a decision by a health plan or health insurer delaying, denying, or modifying a health care service based in whole or in part on medical necessity, to be reviewed by a peer physician or health care professional of the same or similar specialty as the requesting provider. AB 510 was held on the Assembly Appropriations Committee suspense file.
- AB 512 (Harabedian) of 2025, would have required health plan and health insurer decisions based on medical necessity to approve, modify, or deny requests by providers prior to the provision of health care services to enrollees to be made in a timely fashion appropriate for the nature of the enrollee’s condition, not to exceed 48 hours for standard requests, or 24 hours for urgent requests, from the plan’s receipt of the information reasonably necessary and requested by the plan to make the determination. AB 512 was vetoed by Governor Newsom, who said in part:
“I strongly support the goal of improving the PA process. Accordingly, I recently signed SB 306 (Becker), which seeks to ensure that enrollees receive timely responses to requests for care by taking a holistic approach to improve the PA process. Under this new law, health plans and health insurers are required to submit data to DMHC and CDI, respectively, regarding the types of health care services subject to PA requirements. The departments must analyze the data and then issue a list of services that should not be subject to a PA requirement by 2027.”
- AB 539 (Schiavo) of 2025, would have required a PA for a health care service to remain valid for a period of at least one year from the date of approval. AB 539 is a two-year bill in the Senate Health Committee.
- AB 574 (Mark González) of 2025, would have prohibited a health plan or health insurer that provides coverage for physical therapy (PT) from requiring PA for the initial 12 treatment visits for a new condition for PT. For a recurring condition, this bill would have allowed a health plan or insurer to impose PA if the individual seeks care within 180 days of their last physical therapy intervention for that condition. AB 574 was vetoed by Governor Newsom whose veto message was similar to that for AB 512.
- AB 669 (Haney) of 2025, would have prohibited concurrent or retrospective review of medical necessity for the first 28 days of in-network inpatient SUD stay. Would have prohibited concurrent or retrospective review of medical necessity of in-network outpatient SUD visits. Would have prohibited retrospective review of medical necessity for the first 28 days of in-network intensive outpatient or partial hospitalization SUD services, as specified. Would have prohibited PA for in-network coverage of medically necessary outpatient prescription drugs to treat SUD. AB 669 was held on the Senate Appropriations Committee suspense file.
- SB 516 (Skinner) of 2024, would have required DMHC and CDI, by July 1, 2025, to issue instructions, including a standard reporting template, to health plans and insurers to report specified information, including all covered health care services, items, and supplies subject to PA. SB 516 was not heard in the Assembly Health Committee.
- SB 598 (Skinner) of 2023, would have prohibited a health plan or insurer from requiring a contracted health professional to complete or obtain a PA for any covered health care services if the plan or insurer approved or would have approved not less than 90% of the PA requests they submitted in the most recent completed one-year contracted period. SB 598 was held on suspense in the Assembly Appropriations Committee.
- SB 250 (Pan) of 2022 was similar to SB 598 and was held on suspense in the Assembly Appropriations Committee.
- AB 1880 (Arambula) of 2022 would have required a health plan or insurer's UM process to ensure that an appeal of a denial, is reviewed by a clinical peer, as specified. Would have defined clinical peer as a physician or other health professional who holds an unrestricted license or certification from any state and whose practice is in the same or a similar specialty as the medical condition, procedures, or treatment under review. AB 1880 was vetoed by Governor Newsom who stated in part:
“Health plans and health insurers should make every effort to streamline UM processes and reduce barriers to all medically necessary care. However, the bill's requirements, which are limited to denied authorizations for prescription drugs, are duplicative of California's existing independent medical review requirements, which provide enrollees, insureds, and their designated representatives with the opportunity to request an external review from an independent provider. I encourage the Legislature to pursue options that leverage existing requirements and resources, rather than creating duplicative new processes.”
- AB 1268 (Rodriguez) of 2019 would have required a health plan or health insurer, on or before July 1, 2020, and annually on July 1 thereafter, to report to the appropriate department the number of times in the preceding calendar year that it approved or denied each of the 30 health care services for which prospective review was most frequently requested. AB 1268 was held on suspense in the Assembly Appropriations Committee.
REGISTERED SUPPORT / OPPOSITION:
Support
Aids Healthcare Foundation
American Academy of HIV Medicine California/Hawaii Steering Committee
Bartz-Altadonna Community Health Center
Beyond Aids Foundation
California Academy of Preventive Medicine
California Life Sciences Association
California STD/HIV Controller's Association - Executive Committee
Community Health Project LA
County Health Executives Association of California
End Hep C SF
Glide
Health Officers Association of California
Healthright 360
Insurance Commissioner Ricardo Lara / California Department of Insurance
Kedren Health
National Health Law Program
San Francisco Aids Foundation
Sunburst Projects
One individual
Opposition
Association of California Life & Health Insurance Companies
California Association of Health Plans
California Small Business Association
Analysis Prepared by: Riana King / HEALTH / (916) 319-2097
Bill Author
Bill Co-Author(s):